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ABSTRACT 
Breast cancer is the most common malignancy among women worldwide. Most cases are sporadic, 
but an estimated 5-10% are due to hereditary predisposition. Two major susceptibility genes, 
BRCA1 and BRCA2, have thus far been identified. Germline mutations in BRCA1 and BRCA2
explain the majority of families with both early-onset breast cancer and ovarian cancer, but a 
considerably lower fraction of families with site-specific breast cancer. This suggests the presence 
of other predisposing genes. The contribution of BRCA1 and BRCA2 to breast cancer incidence 
remains also unresolved, presumably because most studies have focused on high-risk families with 
multiple affected relatives, on highly recurrent founder mutations in isolated populations, or on 
patients diagnosed at early age. The aim of this study was to examine the frequency of the known 
Finnish BRCA1 and BRCA2 mutations in breast cancer patients unselected for family history and 
age at diagnosis, and to identify clinical risk factors that could be used in predicting the probability 
of finding a BRCA1 or BRCA2 mutation in a family. We also wanted to evaluate the role of p53,
CHEK1, and a newly proposed tumor suppressor gene CHEK2 in multicancer Li-Fraumeni 
syndrome of which breast carcinomas are the major component tumors, and to further assess the 
significance of the identified CHEK2 variant 1100delC in familial breast cancer.  
To estimate the contribution of BRCA1 and BRCA2 germline mutations to breast cancer incidence, 
we analyzed the frequency of the known Finnish mutations in a consecutive series of 1035 
unselected breast cancer patients. Mutations were observed in 1.8% of the patients. The strongest 
predictors of a mutation were the positive family history of ovarian cancer and an early age at breast 
cancer diagnosis. In contrast, the family history of site-specific breast cancer was not strongly 
suggestive of a mutation. The low frequency of BRCA1 and BRCA2 mutations in unselected breast 
cancer patients illustrates that mutation screening is not warranted in the general breast cancer 
population, and confirms that strict criteria needs to be applied when considering genetic testing.  
Identification of predisposing genes has enabled presymptomatic diagnostics of breast cancer 
susceptibility. The mutation screening of BRCA1 and BRCA2 is, however, very laborious and 
expensive, and it may be difficult to distinguish BRCA families from other familial breast cancer 
families or clusters of sporadic cases. In order to be able to better direct the mutation screening to 
potential mutation carrier families, we aimed at identifying the clinical risk factors that associate 
with a positive mutation status. We analyzed 148 families with at least three affected family 
xii
members, and found that the only independent predictors of a mutation were the number of ovarian 
cancer cases in a family and the age at diagnosis of the youngest breast cancer patient. We utilized 
this data and devised a probability model that can be used to assess the likelihood of carrying a 
predisposing BRCA1 or BRCA2 mutation in each family.  
CHEK2 is a checkpoint kinase that has a central role in mediating cellular responses after DNA 
damage. It was first suggested as a susceptibility gene for Li-Fraumeni syndrome (LFS) when 
germline mutations were observed in families with LFS and Li-Fraumeni-like (LFL) syndrome. Our 
analysis of 44 families with LFS, LFL, or breast cancer families with phenotypical features of LFS 
revealed two mutation positive breast cancer patients with family history only suggestive of LFS. 
We further analyzed the frequency of the observed mutation, 1100delC, in a series 1035 newly 
diagnosed breast cancer patients, 507 breast cancer families, and 1885 healthy controls. The 
mutation frequency was slightly elevated among unselected breast cancer patients as compared to 
population controls, and a significantly higher frequency was observed among breast cancer 
families. The 1.4% frequency of the variant among healthy controls, a high frequency in families 
with only a few affected family members, and the presence of healthy carriers in the families 
suggest that the variant acts as a low-penetrance breast cancer susceptibility allele. Despite the low 
penetrance, high frequency of the mutation in families with only a few affected relatives, the most 
common type of breast cancer families, suggests that the allele is likely to make a significant 
contribution to familial clustering of breast cancer. This data also indicates that CHEK2 is unlikely 
a susceptibility gene for LFS, and still other unknown genes lie behind this cancer predisposition 
syndrome.  
1. INTRODUCTION 
Breast cancer is the most common malignancy affecting women worldwide. Up to every eighth 
woman will develop it during lifetime. Most cases are sporadic, but an estimated 7% are due to 
dominantly inherited predisposition, with germline mutations in predisposing genes (Claus et al., 
1996). Thus far, two highly penetrant susceptibility genes, BRCA1 and BRCA2, have been identified 
(Miki et al., 1994; Wooster et al., 1995). Germline mutations in BRCA1 and BRCA2 explain the 
majority of families with both breast and ovarian cancer, whereas vast majority of familial 
aggregation of site-specific breast cancer appears to be caused by other, as yet unidentified genes 
(Ford et al., 1998). Identification and characterization of genes predisposing to hereditary cancer 
may help to unravel the genetic background, etiology, and pathogenesis of cancer in question, and 
eventually lead to better diagnostics and patient management. 
The contribution of BRCA1 and BRCA2 to breast cancer incidence remains largely unknown, as 
most studies have concentrated on families with multiple affected family members, on isolated 
populations, or on young patients. Results from such studies may not be used to assess the 
contribution of BRCA1 and BRCA2 in other populations, in patients without such a strong family 
history of cancer, or in patients with later-onset disease.  
Breast cancer is a common disease, and it may be hard to distinguish BRCA1 and BRCA2 families 
from other familial breast cancer families or clusters of sporadic cases.  It is therefore important to 
identify phenotypic features that could help in identifying families at high risk of carrying a 
predisposing mutation. Identification of disease-associated mutations enables the utilization of the 
specific management strategies that have been defined for mutation carriers, and releases the non-
carriers from the excessive cancer risk.  
The aim of this thesis was to evaluate the frequency of the known Finnish BRCA1/2 mutations in 
unselected breast cancer patients, determine the clinical risk factors that associate with a positive 
BRCA1/2 mutation status, and to assess the role of a newly proposed cancer susceptibility gene 
CHEK2 in breast cancer and in Li-Fraumeni syndrome of which breast cancer is part of.  
1
2. REVIEW OF THE LITERATURE 
2.1. Cancer 
Cancer is a genetic disease that arises from an accumulation of mutations in critical genes. This 
allows a cell to escape the normal growth control and proliferate until it becomes a clinically 
evident tumor. Six acquired capabilities common to human tumor cells have been identified: they 
keep proliferating even in the absence of growth signals, disregard growth-inhibitory signals, evade 
apoptosis, have limitless replicative potential, sustain angiogenesis to guarantee a continuous supply 
of nutrients and oxygen, and are capable of invading tissues and form metastasis (Hanahan & 
Weinberg, 2000). These properties give the cancer cells a growth advantage over the general cell 
population. Based on epidemiological and in vitro experiments, it has been estimated that between 
four and eight successive mutations are needed for the normal human cell to turn malignant (Renan, 
1993; Hahn et al., 1999). Given the multiple defense mechanisms that protect the cells from cancer 
development, this leads to a very low likelihood that a single cell will accumulate the requisite 
number of independent mutations needed for neoplastic transformation. Therefore, it has been 
suggested that tumor cell genomes must acquire increased mutability in order for the tumorigenesis 
to reach completion during a human life span (Loeb, 1991). Indeed, the mutation frequency has 
been estimated to be up to 1000-fold higher in tumor cells than in normal cells (Seshadri et al., 
1987). 
Cancer touches millions of people, as more than 10 million new cancer cases are being diagnosed 
and more than 6 million people die of cancer each year (Parkin et al., 2001). In terms of incidence, 
the most common cancers are lung (12% of all cancer cases), breast (10%), and stomach (9%) 
cancers, while the most common causes of death due to cancer are cancers of the lung (18% of all 
cancer deaths), stomach (10%), and liver (9%). Five most common cancer types in males and 
females are presented in table 1.  
Table 1. Leading primary sites of cancer and number of new cases in the year 2000 in Finland and worldwide (the 
Finnish Cancer Registry, 2003; Parkin et al. 2001) 
                                  Finland                                            World* 
Male   Female  Male   Female  
Prostate 3397  Breast 3683 Lung 902 000  Breast 1 050 000
Lung 1424  Colon/rectum 1081 Prostate 543 000  Cervix uteri 471 000
Colon/rectum 981  Corpus uteri 703 Stomach 558 000  Colon/rectum 446 000
Bladder 573  Lung 494 Colon/rectum 499 000  Lung 337 000
NHL§ 459  NHL§ 468 Liver 398 000   Stomach 318 000
Total  10 913 new cases   Total  11 418 new cases Total  5 318 000 new cases  Total  4 738 000 new cases 
§Non-Hodgkin’s lymphoma; *estimation
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2.2. Hereditary predisposition to cancer 
The vast majority of genetic alterations in cancer are somatic, and thus found only in the tumors of 
the affected individuals. In hereditary cancer, on the other hand, the gene defects are in the 
germline, and therefore present in every cell of the body. Although additional somatic genetic 
aberrations are needed for cancer development, the presence of a germline mutation greatly speeds 
up the process of accumulation of mutations needed for malignant conversion. Individuals with 
such mutations are not only at higher risk at developing cancer, but they are more likely to do so at 
younger age than the general population, and also their risk for developing multiple primary tumors 
is greatly increased. Therefore, the possibility of an inherited cancer syndrome should be considered 
when numerous family members develop cancer at an especially young age or affected individuals 
develop multiple primary tumors (Fearon, 1997). Also congenital abnormalities or other rare 
conditions in families with multiple cancer patients should arouse suspicion of a cancer syndrome, 
and some cancers such as retinoblastoma are so rare that the diagnosis itself warrants further 
evaluation for the possibility of inherited predisposing mutation (Fearon, 1997). Some pathological 
features may further suggest the possibility of hereditary cancer. For example, breast carcinomas 
associated with mutations in the BRCA1 gene are more likely to be of medullary histology and less 
likely to express estrogen receptor than sporadic tumors (the Breast Cancer Linkage Consortium 
1997; Johannsson et al., 1997).  On the other hand, the recognition of hereditary cancer may be 
difficult in some families as the family history may be obscured (Fearon, 1997). This may be due to 
a small family size, uncertain family history, unknown or poorly documented medical records, or 
incomplete penetrance. Germline mutations may also arise spontaneously leading to so called de 
novo mutations. Additionally, sporadic cancers of the same type, especially common carcinomas 
such as breast or colon, may arise in individuals who do not carry germline mutations, making it 
difficult to distinguish true hereditary cancer syndromes from familial clustering formed by chance.  
Several hereditary cancer syndromes have been identified, most of which are very rare (table 2). 
The most common and/or best characterized inherited cancer syndromes include hereditary breast 
and ovarian cancer syndrome (HBOC), hereditary nonpolyposis colorectal cancer (HNPCC), 
familial adenomatous polyposis (FAP), Li-Fraumeni syndrome (LFS), and familial retinoblastoma 
(RB). The genetic background for many cancer syndromes is heterogeneous. For example in 
HNPCC, inherited mutations have been observed in MLH1, MSH2, PMS1, PMS2, MSH6, and 
possibly also in MSH3 (reviewed in Peltomäki, 2003). On other occasions, mutations in one gene 
may lead to variable disease features, as different mutations in RET lead to thyroid papillary 
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carcinoma, familial medullary thyroid carcinoma, familial multiple endocrine neoplasia syndromes 
MEN2A or MEN2B, or Hirschprung’s disease (Santoro et al., 1999). The likelihood that an 
individual with a germline mutation will develop cancer is variable. It is dependent on the particular 
allele inherited, but also on the modifying effects of various other genes. Also exogenous factors 
such as diet, lifestyle, and different kinds of environmental exposures, as well as endogenous 
mutagens, influence the cancer risk.  
Table 2. Hereditary cancer syndromes. Modified from Marsh & Zori, 2002, with additional information from OMIM at 
www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM. 
Syndrome Predominant tumors Known 
gene(s)
Gene 
location
Protein function 
A. Dominantly inherited cancer syndromes    
Carney complex Pituitary adenoma, testicular, 
thyroid, and breast cancers 
PRKAR1A 17q22-q24 Role in the cAMP pathway 
Beckwith-Wiedemann 
syndrome (BWS) 
Wilms tumor, adrenal 
carcinoma, hepatoblastoma, 
rhabdomyosarcoma 
- 11p15 - 
Cowden’s disease Breast, thyroid, and 
endometrial cancers 
PTEN/TEP1/ 
MMAC1 
10q23 Protein tyrosine phosphatase 
Familial adenomatous 
polyposis (FAP) 
Adenomatous polyps of the 
colorectum, tumors of 
gastrointestinal tract, thyroid 
cancer 
APC 5q21 Regulation of cell proliferation, 
migration, adhesion, and 
chromosomal stability 
Familial melanoma Melanoma, pancreatic cancer p16/CDKN2A 9p21 Cell cycle regulation  
 Melanoma CDK4 12q14 Promotion of cell cycle progression 
Hereditary breast and  Breast and ovarian cancer BRCA1 17q21 Maintenance of genomic integrity 
ovarian cancer (HBOC) Female/male breast, ovarian, 
prostate, and pancreatic 
cancer 
BRCA2 13q12 Maintenance of genomic integrity, 
recombination 
Hereditary nonpolyposis  
colorectal cancer  
Colorectal, gastric, 
endometrial, and ovarian  
MLH1 3p21 DNA mismatch repair 
(HNPCC) cancers, tumors of the biliary MSH2 2p22-p21  
 and urinary tract MSH6 2p16
PMS1 2q31-q33  
PMS2 7p22
Hereditary papillary 
renal cell carcinoma 
Papillary renal cell 
carcinoma 
MET 7q31 Transmembrane receptor tyrosine 
kinase 
Hereditary 
paraganglioma and 
phaeochromocytoma 
Paraganglioma, 
phaeochromocytoma 
SDHD 
SDHC 
SDHB 
11q23
1q21
1p36-p35 
Subunits of the mitochondrial 
complex II. Involved in the Krebs 
cycle and the electron transport chain
Hereditary prostate 
cancer (HPC) 
Prostate cancer RNASEL 
ELAC2 
MSR1 
-
-
-
-
1q24
17p11
8p22-p23 
1p36
1q42-q43 
20q13
Xq27-q28 
Ribonuclease, regulation of cell 
proliferation and apoptosis 
Unknown, includes a putative metal-
dependent hydrolase domain 
Modification of reactive oxygen 
intermediates, pathogen removal 
-
-
-
-
Juvenile polyposis (JP) Juvenile polyps in the 
gastrointestinal tract, tumors 
of the colorectum and 
gastrointestinal tract 
SMAD4/DPC4 18q21 Cytoplasmic mediator in the TGF-β
signaling pathway 
BMPR1A  10q21-q22 Serine/threonine kinase type 1 
receptor 
Li-Fraumeni syndrome 
(LFS) 
Sarcomas, breast cancer, 
brain and adrenocortical 
tumors, leukemia 
p53 17p13 Transcription factor, cell cycle 
regulation, apoptosis 
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Multiple endocrine 
neoplasia type 1 (MEN1) 
Pituitary and pancreatic islet 
cell tumors  
MEN1 11q13 Mediator of JunD transcriptional 
activity, possible role in TGF-β
signaling 
Multiple endocrine 
neoplasia type 2 (MEN2) 
Medullary thyroid 
carcinoma, 
phaeochromocytoma 
RET 10q11 Transmembrane receptor tyrosine 
kinase 
Multiple exostoses  Exostoses EXT1 
EXT2 
EXT3 
8q24
11p11-p13 
19p
Bone growth control 
Neurofibromatosis type 1 
(NF1) 
Neurofibrosarcoma, 
astrocytoma, melanoma, 
rhabdomyosarcoma, chronic 
myeloid leukemia 
NF1 17q11 Negative regulator of RAS-mediated 
cellular proliferation 
Neurofibromatosis type 2 
(NF2) 
Neurofibrosarcoma, 
astrocytoma, meningioma, 
schwannoma, spinal and skin 
tumors  
NF2 22q12 Maintenance of the cytoskeleton, 
suppressor of cell adhesion, motility 
and spreading 
Nevoid basal cell 
carcinoma 
Basal cell carcinoma PTCH 9q22 Development, negative regulator of 
cell division 
Palmoplantar 
keratoderma 
Esophageal tumors - 17q25 - 
Peutz-Jeghers syndrome 
(PJS) 
Intestinal hamartomas, 
tumors of gastrointestinal 
tract, breast and testicular 
cancer, gyneocological 
tumors 
LKB1/STK11 19p13 Serine/threonine kinase 
Retinoblastoma Retinoblastoma RB 13q14 Cell cycle regulation, apoptosis 
Tuberous sclerosis Hamartomas, renal cell 
carcinoma, astrocytoma 
TSC1 9q34 Maintenance of the cytoskeleton 
TSC2 16p13
von Hippel-Lindau 
syndrome (VHL) 
Renal cell carcinoma, retinal 
and central nervous system 
hemangioblastomas 
VHL 3p25 Promotes fibronectin matrix 
assembly, component of a ubiquitin 
ligase complex 
Wilms tumor Wilms tumor (pediatric 
kidney tumor) 
WT1 11p13 Transcriptional regulation 
    
B. Recessively inherited cancer syndromes    
Ataxia-telangiectasia 
(AT)  
Lymphoma, leukemia, breast 
cancer 
ATM 11q23 DNA damage recognition, protein 
kinase 
Bloom’s syndrome Solid tumors of multiple 
sites, leukemia, lymphoma 
BLM 15q26 DNA helicase 
Fanconi anemia Acute myeloid leukemia, 
tumors of gastrointestinal 
tract, gynecological tumors 
FANCA 
FANCC 
FANCD2 
16q24
9q22
3p25.3 
Maintenance of genomic integrity 
FANCE 6p22
FANCF 11p15
FANCG 9p13
BRCA2 13q12
Rothmund-Thomson 
syndrome 
Sarcomas, basal cell 
carcinoma, squamous cell 
carcinoma 
RECQL4 8q24 DNA helicase 
Werner syndrome Osteosarcoma, meningioma WRN 8p12 DNA helicase and exonuclease 
Maintenance of genomic instability 
Xeroderma pigmentosum Basal cell carcinoma,  XPA 9q22 DNA repair after ultraviolet  
 melanoma XPB 2q21 radiation 
XPC 3p25
XPD 19q13
XPE 11p12
XPF 16p13
XPG 13p32
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2.2.1. Genes involved in hereditary cancer 
2.2.1.1. Oncogenes 
Under normal conditions, proto-oncogenes stimulate cell growth and differentiation required e.g. 
for the continuous renewal of epithelial cells. When inappropriately activated, they may turn into 
cancerous oncogenes and continue to grow −or refuse to die−, even in the absence of growth 
signals. At the cellular level oncogenes are dominant, meaning that mutation in one allele alone can 
promote uncontrolled cell proliferation. At present, over 100 oncogenes have been identified. 
Inherited mutations in those are, however, relatively rare, presumably because such mutations 
remove normal control over cell growth, thereby being lethal during embryogenesis and leading to 
spontaneous termination of pregnancy (Frank, 2001). Only three oncogenes have been shown to be 
involved in hereditary cancer syndromes, namely RET in thyroid cancer, CDK4 in melanoma, and 
MET in papillary renal cell carcinoma (Mulligan et al., 1993; Zuo et al., 1996; Schmidt et al., 1997). 
2.2.1.2. Tumor suppressor genes 
Tumor suppressors negatively regulate cell proliferation either through controlling the cell division 
or by promoting programmed cell death. According to Knudson’s “two-hit” hypothesis both copies 
of the tumor suppressor gene have to be inactivated in order for the cell to turn malignant (Knudson, 
1971). In hereditary cancer one defective allele is inherited and the function of the remaining allele 
is lost by a somatic mutation. Traditionally, the second hit is considered to be a large deletion that 
can be visualized by the loss of heterozygosity (LOH) in the corresponding tumor (Ponder, 1988). 
However, recent evidence suggest haplo-insufficiency in a growing number of tumor suppressor 
loci (Fero et al., 1998; Tang et al., 1998; Venkatachalam et al., 1998; Wetmore et al., 2000; Xu et 
al., 2000; Kwabi-Addo et al., 2001; Buchholz et al., 2002), indicating that bi-allelic inactivation of 
these genes may not be necessary at least for the initiation of tumorigenesis.  
According to function, tumor suppressors have been further divided into gatekeepers and caretakers 
(Kinzler & Vogelstein, 1997). Gatekeepers prevent malignant transformation directly by regulating 
proliferation, promoting differentiation, or by inducing cell death, whereas caretakers prevent 
neoplasia indirectly by maintaining genomic integrity through DNA repair and replication. In a 
third class of tumor suppressors, landscapers, the genetic defect is not in the transforming cell 
population itself but rather in adjacent stromal cells which promote malignancy of the associated 
cells due to an abnormal intercellular signaling (Kinzler & Vogelstein, 1998). Recently, a new class 
of tumor suppressors was proposed (Liu et al., 2000). These genes encode proteins that are essential 
for the cell survival and only modestly enhance tumorigenesis in a heterozygous form (e.g. CHEK1
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and ATR). So far, more than 30 tumor suppressor genes have been identified, and inactivating 
mutations in them cause most of the inherited cancer syndromes.  
2.3. General features of breast cancer 
Breast cancer is by far the most common cancer type among women worldwide, with a million new 
cases being diagnosed each year (Parkin et al., 2001). The lifetime cumulative risk of developing 
breast cancer in western populations is in the order of 10% (Hopper, 2001). Besides female gender, 
age, and family history of disease, significant risk determinants include several reproductive and 
hormonal factors such as early menarche, late menopause, late age at first childbirth, nulliparity, 
short breastfeeding, use of oral contraceptives, and hormone replacement therapy, which all 
increase the exposure of breast tissue to estrogen (reviewed in McPherson et al., 2000; Hulka & 
Moorman, 2001). The effect of estrogen is also seen in age-specific breast cancer rates, as the 
incidence increases with age doubling about every 10 years until the menopause, after which the 
rate of increase slows considerably (McPherson et al., 2000). Also postmenopausal obesity, alcohol 
consumption, high socio-economic status, exposure to radiation, and previous benign breast disease 
have been associated with increased breast cancer risk (McPherson et al., 2000; Hulka & Moorman, 
2001). The higher breast cancer incidence in Western countries compared to most developing 
countries may be at least partly due to differences in these reproductive, dietary, and lifestyle 
factors (Pike et al., 1983; Newcomb et al., 1994). This is in agreement with the estimation that late 
age at first birth/nulliparity and high income account for 30% and 19% of breast cancer cases in the 
U.S., respectively (Madigan et al., 1995).  
About 95% of malignant breast tumors are carcinomas, i.e. they originate from the epithelium of the 
mammary gland. Neoplastic transformation of a carcinoma typically proceeds from a benign, well-
differentiated tumor through a local tumor, carcinoma in situ, ultimately to invasive cancer with a 
potential to send metastasis to other parts of the body.  Histologically the most common breast 
tumors are infiltrating ductal (70%) and lobular (6%) carcinomas, while the rare histological 
subtypes such as medullary, mucinous, papillary, or tubular carcinomas, or Paget’s disease each 
contribute only a small proportion (Berg & Hutter, 1995).     
In Finland, 3 683 new female breast cancer cases were reported in the year 2000, and the annual 
numbers appear to be growing (the Finnish Cancer Registry, 2003). Along with the increase in 
breast cancer incidence, the prognosis has markedly improved during the last decades, mostly due 
7
to effective screening programs and improved treatment. The five-year relative survival rate (RSR) 
is nowadays about 80%, but there is still large variation between patients according to the clinical 
stage at the time of diagnosis: the five-year RSR is 93% for patients with localized disease, 69% for 
patients with regional metastases, and 22% for patients with distant metastases (Dickman et al., 
1999). 
Breast cancer occurs also in males, although very rarely. In the year 2000, eleven new cases were 
diagnosed in Finland (the Finnish Cancer Registry, 2003). Predisposing factors include increased 
estrogen and decreased androgen exposure, a family history of either male or female breast cancer, 
and mutations in the BRCA2 gene (Sasco et al., 1993; Friedman et al., 1997; Haraldsson et al., 
1998). Isolated cases have also been reported in families with Cowden’s disease, HNPCC, and 
Reifenstein syndrome, with germline mutations in PTEN, MLH1, and androgen receptor genes, 
respectively (Wooster et al., 1992; Boyd et al., 1999; Fackenthal et al., 2001).  Histologically, 
ductal carcinomas account for more than 95% of the cases (Tischkowitz et al., 2002). No difference 
in the outcome have been found between sexes in matched studies (Tischkowitz et al., 2002), but 
male cancers are more likely to be of high grade and overexpress estrogen and progesterone 
receptors as well as to show lower expression of p53 and ERBB2 (Muir et al., 2003). These 
differences may have impact on treatment strategies and have even led to the suggestion of different 
pathogenesis in the evolution and progression of the disease in males (Muir et al., 2003).  
2.4. Hereditary breast and ovarian cancer syndrome 
A familial component to female breast cancer has long been recognized. First formal documents 
were published already more than a hundred years ago by Paul Broca, who reported on a family in 
which 10 out of 24 women in four successive generations had died of breast cancer, and where 
several other individuals had suffered other malignancies (reviewed in Schildkraut et al., 1989; 
Steel et al., 1991). He also concluded that the observed large excess of cancer cases could not be 
explained by chance. With the improved methodologies and more carefully designed study 
protocols this hypothesis was specified in the early decades of the 20th century, when a consistent 
excess of breast cancer was observed among breast cancer patients’ relatives in several studies 
(Schneider et al., 1986). An association between breast and ovarian carcinomas was first proposed 
in the 1970’s on the basis of large families with an excess of both cancer types (Lynch et al., 1978), 
and an observed genetic correlation further supported the existence of hereditary breast and ovarian 
cancer syndrome (Schildkraut et al., 1989). In the mid 1990’s the genetic basis for the majority of 
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HBOC-families was finally established when the major predisposing genes, BRCA1 and BRCA2,
were identified (Miki et al., 1994; Wooster et al., 1995). 
2.4.1. Major breast and ovarian cancer susceptibility genes BRCA1 & BRCA2 
2.4.1.1. Identification, structure, and expression  
Two major genes predisposing to breast and ovarian cancer, BRCA1 and BRCA2, have been 
identified by genetic linkage and positional cloning methods. BRCA1, located on chromosome 
region 17q21, comprises of 24 exons of which 22 encode a protein of 1863 amino acids (Hall et al., 
1990; Miki et al., 1994; Smith et al., 1996). It has two alternative transcription start sites in non-
translated exons 1a and 1b (Xu et al., 1995). The BRCA2 gene resides on chromosome region 13q12 
and is even larger than BRCA1; 26 of its 27 exons encode a protein of 3418 amino acids (Wooster et 
al., 1994, 1995; Tavtigian et al., 1996). Both genes have very large middle exons, as exon 11 of 
BRCA1 and exons 10 and 11 of BRCA2 encode over 60% of the proteins. 
Although BRCA1 and BRCA2 bear only little resemblance to one another or to proteins with 
known function, they contain some structural motifs that yield clues to their biochemical functions. 
The N-terminal end of BRCA1 has a zinc-binding domain (aa 24-64) with a conserved pattern of 
cysteine and histidine residues (Miki et al., 1994). This so called RING-finger is found in a wide 
variety of proteins and it appears to be involved in protein-protein interactions (Saurin et al., 1996). 
In BRCA1 it is part of a larger structural motif (aa 1-109) that is responsible e.g. for BRCA1 
homodimer and BRCA1-BARD1 and BRCA1-BAP1 heterodimer formation (Wu et al., 1996; 
Brzovic et al., 1998; Jensen et al., 1998). Two nuclear localization signals that are required for 
translocation from the cytoplasm are located in exon 11 (Chen et al., 1996). The C-terminal end 
contains two BRCT (BRCA1 C-terminal) domains that interact with multiple transcription 
activators and repressors (Koonin et al., 1996). The structure of BRCA2 is less well characterized. 
The currently recognized structural motifs include eight repeated BRC-sequences in the central part 
of the protein that interact directly with RAD51 (Bork et al., 1996; Wong et al., 1997). Recently, a 
crystal structure of C-terminal end revealed three oligonucleotide binding folds that bind single 
stranded DNA directly (Yang et al., 2002a). In addition, there are at least two functional domains, 
as the N-terminal region is suggested to have a role in transcriptional regulation (Milner et al., 
1997), and two nuclear localization signals are found at the C-terminus (McAllister et al., 1997).  
Both protein products are ubiquitously expressed in a wide variety of human tissues, with the 
highest levels seen in testis and thymus (Miki et al., 1994; Tavtigian et al., 1996). Mouse studies 
9
have revealed the up-regulation specifically in rapidly dividing and differentiating tissues, including 
breast epithelial cells during puberty and pregnancy (Marquis et al., 1995; Rajan et al., 1997). At 
the cellular level the expression pattern is cell-cycle dependent, with peaks observed at the G1/S 
boundary (Gudas et al., 1996; Rajan et al., 1996; Vaughn et al., 1996a, b). Especially BRCA1 
associates with many proteins, with complex formation changing dynamically during cell cycle and 
after different kinds of DNA damage. For example, during the S phase BRCA1 co-localizes with 
BRCA2 and RAD51 in nuclear foci (Scully et al., 1997b), but upon DNA damage it becomes 
rapidly phosphorylated and components of the foci are re-distributed to the sites of replication 
(Scully et al., 1997a). BRCA1 and BRCA2 also stably interact with each other (Chen et al., 1998).  
Schematic presentation of the BRCA proteins is presented in figure 1. 
Figure 1. BRCA1 and BRCA2 proteins. Structural domains and functional motifs are indicated with boxes, 
and some of the most important interacting proteins are marked below the proteins. The borders of exons 11 
are indicated with black lines. The ovarian cancer cluster region (OCCR) is shown above BRCA2. NLS, 
nuclear localization signal. See text and table 3 for more details. Modified from Borg, 2001. 
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2.4.1.2. Proposed functions 
BRCA1 and BRCA2 are multifunctional proteins that are involved in many fundamental cellular 
processes. Multiple functions are mediated primarily through interactions with other proteins, which 
are presented in table 3. One main function of BRCA1 and BRCA2 is to participate in maintaining 
genomic integrity. This is mediated in part through participating in DNA repair, especially after 
double-strand breaks (DSB). BRCA1 is proposed to participate in the initiation of the repair as it 
binds DNA directly, preferentially at sites of branched DNA (Yamane et al., 2000; Paull et al., 
2001). It is also part of a SWI/SNF chromatin-remodeling complex where it may function to direct 
chromatin remodeling to the site of DNA damage and/or to activate genes involved in damage 
repair (Bochar et al., 2000). Interaction with DNA helicase BACH1 suggests that it may participate 
in the unwinding of DNA at sites of damage (Cantor et al., 2001). BRCA1 mediates genomic 
stability also through a so called BRCA1- associated genome surveillance complex (BASC), which 
contains many known DNA repair enzymes as well as proteins involved in replication and 
recombination (Wang et al., 2000). All of these proteins possess the ability to recognize abnormal 
DNA structures and may therefore act as sensors of these aberrations. BRCA1 is proposed to have a 
central role in BASC, acting as a scaffold that both organizes and coordinates the multiple activities 
required to maintain genomic integrity (Wang et al., 2000). The role of both BRCA1 and BRCA2 in 
homologous recombination is indicated by the association with RAD51, a mammalian homologue 
of Escherichia coli RecA that is required for recombination during mitosis and meiosis as well as in 
recombinational repair of DSBs in DNA (Shinohara et al., 1992; Scully et al., 1997b; Wong et al., 
1997). The role of BRCA2 in homologous recombination may be more direct, as it is suggested to 
control the intracellular transport and enzymatic activity of RAD51 (Davies et al., 2001). BRCA1 
and BRCA2 protect the cell against genomic instability also through controlling centrosome 
duplication, chromosome condensation, and the appropriate segregation of chromosomes to 
daughter cells (Marmorstein et al., 2001; Deng, 2002). This explains the accumulation of 
chromosomal abnormalities such as chromosomal breaks, centrosome amplification, and severe 
aneuploidy in the absence of BRCA1 and BRCA2 protein products (Patel et al., 1998; Xu et al., 
1999b). As BRCA1 and BRCA2 have crucial roles in maintaining genetic stability, their 
inactivation leads to increased probability that mutations will accumulate in other genes that are 
critical for neoplastic transformation. This has been observed particularly with tumor suppressor 
p53 as somatic p53 mutations are more frequently found in BRCA1 and BRCA2 associated tumors 
than in sporadic tumors (Crook et al., 1998; Ramus et al., 1999).  
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Table 3. Proteins that interact with, or directly belong to, the BRCA1 and BRCA2 signaling pathway. 
Adapted from Borg, 2001 and Welcsh & King, 2001. 
BRCA1 interacting protein Function                 Interacting BRCA1 domain (aa) 
ID4  transcriptional activation  - 
E2F  transcription factor, cell cycle regulator N-terminus (1-76) 
BARD1  ubiquitine ligase, polyadenylation RING (1-109) 
BAP1  ubiquitine hydrolase  RING (1-109) 
ATF1  transcription factor  N-terminus (1-300) 
ERα  ligand responsive transcription factor N-terminus (1-300) 
c-Myc  transcription factor, oncogene  N-terminus and exon 11 (175-303,  
433-511)
p53  transcription factor, tumor suppressor exon 11 and BRCT domain (224-500, 
1760-1863) 
SWI/SNF complex chromatin remodelling complex  exon 11 (260-553) 
VCP  ATPase   exon 11 (303-625) 
KPNA2/importin α nuclear transport  NLS (503-508, 606-615) 
ZBRK1  transcription repressor  exon 11 (341-748) 
RAD50  DNA DSB-repair and NHEJ  exon 11 (341-748) 
STAT1α  signal transduction, transcriptional activation exon 11 (502-802) 
BRAP2  cytoplasmic retention  NLS (503-656) 
RAD51  homologous recombination  exon 11 (758-1064) 
AR  ligand responsive transcription factor exon 11 and BRCT domain  
(758-1064, 1314-1863) 
CBP/p300  transcription co-activator  RING and BRCT domains (1-303,  
1314-1863) 
BACH1   DNA helicase   BRCT domain (1529-1863) 
HDAC1  histone deacetylase  BRCT domain (1536-1863) 
HDAC2  histone deacetylase  BRCT domain (1536-1863) 
RB  transcription repressor  exon 11 and BRCT domain (304-394, 
 1536-1863) 
RbAp46  histone deacetylase  BRCT domain (1536-1863) 
RbAp48  histone deacetylase  BRCT domain (1536-1863) 
RHA  RNA helicase A  BRCT domain (1650-1800)? 
RNA Pol II holoenzyme II  transcription   BRCT domain (1650-1800)? 
(RPB10α, RPB2)   
CtIP  transcription repressor  BRCT domain (1651-1863) 
CHEK1  checkpoint kinase 
CHEK2  checkpoint kinase  Ser988 
ATM  checkpoint kinase  Ser1423/1524 
ATR  checkpoint kinase  Ser1423 
NBS1  DNA DSB-repair and NHEJ  ? 
MRE11  DNA DSB-repair and NHEJ  ? 
FANCD2  DNA repair   ? 
BLM  DNA repair   ? 
H2AX  DNA damage signaling  ? 
Casein kinase 2     Ser 1572? 
CDK2-cyclin E  checkpoint kinase  Ser 1497?  
CDK2-cyclin A  checkpoint kinase  ? 
BASC (ATM, BLM, MSH2,  BRCA1 part of a complex 
MSH6, MLH1, RCF) 
Centrosome (p53, pRB, Nm23) BRCA1 part of a complex 
BRCA2 interacting protein Function Interacting BRCA2 domain (aa)
P/CAF1   histone acetyltransferase  N-terminus (290-453) 
RAD51  homologous recombination  exon 11 BRC repeats (1009-2083),
    and C-terminus (3196-3232)
BRAF35  chromatin condensation  exon 11 BRC repeats (1648-2190) 
DSS1  cell cycle control  C-terminus (2472-2957) 
hBUBR1  mitotic checkpoint kinase C-terminus (2861-3176) 
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BRCA1 and BRCA2 are also involved in regulating transcription. This is mediated through direct 
interaction with transcription factors and/or with the components of the transcriptional machinery 
(Chapman & Verma, 1996; Milner et al., 1997; Fuks et al., 1998; Monteiro, 2000). Both protein 
products are involved in controlling the cell cycle as well (Lee et al., 1999; Xu et al., 1999b; 
Marmorstein et al., 2001; Yarden et al., 2002). Recently, both BRCA1 and BRCA2 were linked to 
Fanconi Anemia (Garcia-Higuera et al., 2001; Howlett et al., 2002). They may also act directly in 
suppressing tumor growth, as they are shown to repress proliferation in vitro and inhibit tumor 
formation in vivo (Holt et al., 1996; Wang et al., 2002). Mouse studies have revealed their 
importance in embryogenesis, as knock-out mice die during gestation (Hakem et al., 1996; Ludwig 
et al., 1997). BRCA1 has also been associated with X-chromosome inactivation in females (Buller 
et al., 1999; Ganesan et al., 2002), and it may facilitate ubiquitination when targeting proteins for 
degradation (Lorick et al., 1999). BRCA1 may also trigger apoptosis through interactions with 
GADD45 (Harkin et al., 1999), p53 (Xu et al., 2001), and γ-interferon (Andrews et al., 2002). 
Although implicated in numerous cellular processes, all various functions of BRCA1 and BRCA2 
promote the maintenance of genetic stability both during normal cell cycle as well as after exposure 
to DNA damaging agents. Further information on protein structures and interactions with other 
polypeptides will shed more light into precise biochemical functions of BRCA1 and BRCA2, as 
well as on their specific roles in tumor development.   
2.4.1.3. Predisposition to cancer 
Germline mutations in BRCA1 and BRCA2 predispose individuals particularly to breast and ovarian 
cancer. This tissue-specific predisposition may, at least in part, be explained by the association with 
estrogen. During puberty and pregnancy the estrogen level increases dramatically, leading to rapid 
proliferation of breast epithelium and formation of clonal breast lobules. In individuals with 
hereditary BRCA1 or BRCA2 mutation the entire lobule carries the predisposing mutation and 
thereby the risk of developing subsequent mutations needed for neoplastic progression is greatly 
amplified (Scully & Livingston, 2000). Normally, the expression of BRCA1 and BRCA2 increases 
in response to rapid proliferation, possibly providing a protective negative feedback loop against 
proliferative burst caused by estrogen (Rajan et al., 1996; Fan et al., 1999; Bennett et al., 2000). The 
responsiveness of breast and ovaries to estrogen in itself may also explain the tissue-specificity of 
cancers, as some estrogen metabolites are shown to damage DNA, promote genomic instability, and 
induce mutations (Fishman et al., 1995; Cavalieri et al., 2000). In the absence of functional BRCA1 
and BRCA2 the cells are incapable of repairing these damages. Tissue-specific carcinogenesis may 
also result from malfunction during mammary gland development, as BRCA1 and BRCA2 are 
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suggested to control proliferation and promote differentiation of the breast (Marquis et al., 1995; 
Rajan et al., 1996, 1997; Xu et al., 1999b). Tissue-specific expression of genes that modify the 
effect of BRCA1 and BRCA2 may play a role as well (Welcsh et al., 2000).  
Besides breast and ovarian carcinomas, hereditary BRCA1 and BRCA2 mutations predispose also to 
cancers at other sites. BRCA1 mutation carriers are suggested to have an increased risk for uterine 
and cervical carcinomas and possibly also for carcinomas of the pancreas, colorectum, and stomach 
(Risch et al., 2001; Thompson & Easton, 2002 and refs. therein). BRCA2 mutations have been 
associated especially with prostate and pancreatic cancers but also with melanoma and cancers of 
the stomach, colorectum, and gallbladder and bile duct (the Breast Cancer Linkage Consortium, 
1999 and refs. therein; Risch et al., 2001). The overall increase in the risk of cancer at sites other 
than the breast and ovaries is quite small, except for the prostate cancer among BRCA2 carriers 
where the cumulative risk has been estimated to be 20-34% by age 80 years (The Breast Cancer 
Linkage Consortium 1999; Thompson & Easton, 2001). The contribution of BRCA2 to pancreatic 
cancer may also be bigger than previously estimated, as germline mutations have been identified in 
about 10% of patients with apparently sporadic disease as well as in 15% of families with familial 
pancreatic carcinoma (Goggins et al., 1996; Ozcelik et al., 1997; Murphy et al., 2002; Hahn et al., 
2003). Altogether, lifetime risk of developing cancer at any site approaches 100% in both BRCA1
and BRCA2 female carriers (the Breast Cancer Linkage Consortium, 1999; Risch et al., 2001). 
2.4.1.4. Risk of breast and ovarian cancer in mutation carriers 
Early studies on high-risk families with multiple affected individuals led to relatively high breast 
cancer penetrance estimations of around 70-85% to age 70 years for both BRCA1 and BRCA2
mutations (Ford et al., 1994, 1998; Easton et al., 1995, 1997; Narod et al., 1995). Since then, lower 
penetrance estimations of 35-69% for BRCA1 and 26-56% for BRCA2 to age 70 years have been 
obtained especially from population-based studies (Struewing et al., 1997; Whittemore, 1997; 
Thorlacius et al., 1998; Hopper et al., 1999; Warner et al., 1999; the Anglian Breast Cancer Study 
Group, 2000; Satagopan et al., 2001; Thompson & Easton, 2001; Antoniou et al., 2002). In a recent 
meta-analysis combining data from 22 studies and involving over 8 000 unselected breast cancer 
patients the average cumulative breast cancer risk was 65% for BRCA1 carriers and 45% for BRCA2
carriers (Antoniou et al., 2003). The risk for subsequent cancer is also high in breast cancer patients 
with mutations in BRCA1 and BRCA2. The estimated cumulative risk for second breast cancer 
varies from 25% to 65%, whereas about one third of BRCA1 and 10% of BRCA2 carriers are 
estimated to develop subsequent ovarian cancer (Ford et al., 1994; Easton et al., 1995; Eerola et al.,  
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2001b).  
The increased risk for male breast cancer has been connected with germline BRCA2 mutations, with 
an estimated cumulative risk of 3-6% by the age 70 years (Easton et al., 1997; Thompson & Easton, 
2001). Also somatic BRCA2 mutations, germline transcript imbalance, and LOH have been 
observed in male breast cancer patients, indicating an even more relevant role for BRCA2 in the 
pathogenesis of male breast carcinomas (Kwiatkowska et al., 2002; Ottini et al., 2003). 
Traditionally, the role of BRCA1 has been estimated to be fairly small in male breast cancer. 
However, altogether nine deleterious germline mutations were found in two recent reports totaling 
101 male breast cancer cases (Frank et al., 2002; Ottini et al., 2003), suggesting that also BRCA1
may contribute a larger fraction to male breast cancer than previously thought.  
The risk for ovarian cancer in the original high-risk families was estimated to be 42-63% for 
BRCA1 and 27% for BRCA2 mutation carriers (Easton et al., 1995; Narod et al., 1995; Ford et al., 
1998). In the population-based studies these estimates have fallen to 22-39% for BRCA1 and 9-21% 
for BRCA2 mutation carriers (the Anglian Breast Cancer Study Group, 2000; Thompson & Easton, 
2001; Antoniou et al., 2002, 2003; Satagopan et al., 2002). The low estimate for BRCA2 may, 
however, be an underestimation, since most studies have focused on early-onset cases and patients 
with strong family histories, whereas BRCA2 mutations are shown to predispose predominantly to 
later-onset cancer, and an appreciable number of mutation carriers do not have many affected 
relatives (Risch et al., 2001).   
Large variation in penetrance estimations is not only due to different type of patient material or the 
various methods that have been used in specific studies, but different mutations may have variable 
impact on cancer risks. Recently, Scott et al (2003) reported on the effect of the mutation type to the 
average cumulative risk. According to their study,  splice-site mutations in both BRCA1 and 
BRCA2, as well as missense substitutions in BRCA2, confer to a very high breast cancer risk of 
about 80%, whereas missense substitutions in the BRCA1 gene have only a 25% average cumulative 
risk. Also the location of a mutation may affect the cancer risk, and an increased risk for ovarian 
cancer together with a reduced breast cancer risk has been suggested in the more upstream part of 
BRCA1 as well as in a so called ovarian cancer cluster region (OCCR) in the central region of the 
BRCA2 gene (Gayther et al., 1995, 1997b; Holt et al., 1996; Risch et al., 2001; Thompson & 
Easton, 2001, 2002). Besides BRCA1 and BRCA2 themselves, there are other genetic factors that 
modify the effect of BRCA1 and BRCA2 mutations. For example, long polyglutamine repeats of the 
AIB1 gene and long CAG-repeats of the androgen receptor gene were shown to increase the breast 
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cancer risk (Rebbeck et al., 1999a, 2001), rare HRAS alleles were observed to increase the ovarian 
cancer risk (Phelan et al., 1996), and a polymorphism in the RAD51 was shown both to increase the 
breast cancer risk and lower the ovarian cancer risk (Wang et al., 2001b) among BRCA1 and/or 
BRCA2 mutation carriers. In addition,  non-genetic factors influence the cancer penetrance in 
BRCA1 and BRCA2 mutation carriers. For instance, pregnancy (Johannsson et al., 1998; Jernstrom 
et al., 1999) and the use of oral contraceptives (Ursin et al., 1997; Narod & Boyd, 2002) are shown 
to increase the breast cancer risk, whereas the risk is decreased by bilateral prophylactic 
mastectomy (Hartmann et al., 2001; Meijers-Heijboer et al., 2001), oophorectomy (Rebbeck et al., 
1999b, 2002), and the use of tamoxifen (Narod et al., 2000). Interestingly, also smoking has been 
shown to reduce the breast cancer risk among BRCA1 and BRCA2 mutation carriers, possibly 
through an antiestrogenic effect (Brunet et al., 1998). The risk of ovarian cancer is reduced by tubal 
ligation (Narod et al., 2001) and the use of oral contraceptives (Narod et al., 1998).     
2.4.1.5. Mutation spectrum 
Since the identification of BRCA1 and BRCA2, numerous studies have been performed worldwide 
and more than 1000 sequence alterations have been reported in both genes (the BIC database). 
Mutations are scattered throughout the large coding regions of the genes, making mutation 
screening challenging both technically and financially. Vast majority of reported mutations are 
small insertions or deletions, nonsense mutations, or alterations affecting the splice-site (the BIC 
database). Many missense substitutions have also been identified, but their role in carcinogenesis is 
much harder to establish, and therefore, most of them are classified as alterations with unknown 
significance (the BIC database).  
The observed mutation spectrum is largely influenced by the techniques used in mutation screening. 
As most studies have used PCR-based methods, large genomic rearrangements and regulatory 
mutations have been missed, and it has been estimated that only 63% of mutations can be detected 
by conventional screening techniques (Ford et al., 1998). And indeed, several large genomic 
rearrangements have recently been identified particularly in BRCA1 (Petrij-Bosch et al., 1997; 
Puget et al., 1997; Swensen et al., 1997; Puget et al., 1999; Rohlfs et al., 2000; the BRCA1 exon 13 
duplication screening group, 2000; Unger et al., 2000; Gad et al., 2002; Hofmann et al., 2002; 
Montagna et al., 2003), and to a lesser extent in BRCA2 (Nordling et al., 1998; Wang et al., 2001a). 
High frequency of such mutations in BRCA1 is thought to result from unusually high concentration 
of Alu-elements in the intronic sequences of the gene, rendering it particularly prone to Alu-
mediated unequal recombination (Smith et al., 1996; Puget et al., 1997).  
16
Most mutations are unique to the families they have been identified in, but in many populations 
recurrent founder mutations also exist. The founder effect is most clearly seen in Iceland, where one 
BRCA2 mutation (999del5) is estimated to account for up to 76% of families with multiple cases of 
female breast cancer and/or male breast cancer (Thorlacius et al., 1996). Population frequency of 
this mutation is estimated to be about 0.5% (Johannesdottir et al., 1996; Thorlacius et al., 1997). 
Strong founder effect is also seen among Ashkenazi Jews, where approximately 2.5% of individuals 
carry one of the three founder mutations (185delAG or 5382insC in BRCA1, 6174delT in BRCA2)
(Roa et al., 1996; Struewing et al., 1997; Hartge et al., 1999). These mutations are estimated to 
account for 45% of high-risk families among Ashkenazis (Tonin et al., 1996). The commonness of 
the mutations is exemplified in one large kindred where all three mutations have been identified 
(Liede et al., 1998). As data on BRCA1 and BRCA2 mutations accumulates, recurrent founder 
mutations are being identified in a growing number of populations. So far these include for example 
French Canadians (Simard et al., 1994; Tonin et al., 1998), Austrians (Wagner et al., 1996), Dutch 
(Petrij-Bosch et al., 1997), Belgians (Goelen et al., 1999), Swedes (Hakansson et al., 1997), 
Russians (Gayther et al., 1997a), British (the BRCA1 exon 13 duplication screening group, 2000), 
Greek (Ladopoulou et al., 2002), African-Americans (Olopade et al., 2003), and Japanese, Chinese, 
Thais, Philippines, and Pakistanis (Liede & Narod, 2002). Founder effect is also evident in Finland, 
where six recurrent BRCA1 and five BRCA2 mutations were shown to account for the majority 
(84%) of BRCA1 and BRCA2 positive families when the whole coding regions and exon-intron 
boundaries were screened (Vehmanen et al., 1997a, b; Huusko et al., 1998). 
2.4.1.6. Prevalence 
Early linkage studies on high-risk families indicated that up to 80-100% of hereditary breast cancer 
susceptibility was due to BRCA1 or BRCA2 (Easton et al., 1993; Narod et al., 1995; Wooster et al., 
1995). A few years later in a large collaborative study where families with at least four cases of 
breast cancer diagnosed below 60 years were analyzed 52% of the families showed linkage to or 
had germline mutations in BRCA1 and 32% in BRCA2 (Ford et al., 1998). The vast majority (81%) 
of families with both breast and ovarian cancer were linked to BRCA1, whereas families with male 
breast cancer cases were mainly (76%) due to BRCA2. Interestingly, substantially smaller 
frequencies were observed in families with four or five female breast cancer cases but no ovarian 
cancer or male breast cancer as only 32% and 9% of such families were linked to BRCA1 or 
BRCA2, respectively (Ford et al., 1998).  
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The prevalence of BRCA1 and BRCA2 germline mutations has been extensively studied in breast 
and/or ovarian cancer families in different populations. A selected series of such studies is 
presented in table 4. In Finland, 20% of high-risk families have been shown to carry a germline 
mutation in BRCA1 (10%) or in BRCA2 (10%) (Vehmanen et al., 1997a, b; Huusko et al., 1998). 
This frequency is lower than reported for most other populations, although the comparison of the 
studies is complicated as families have been selected through different definitions and the methods 
and extents of the screenings have been highly variable. Altogether, it seems that germline 
mutations in BRCA1 and BRCA2 account for about 20-50% of hereditary breast cancer families −a
fraction substantially smaller than originally thought−, and the proportion appears to vary a great 
deal between different populations.  
Table 4. BRCA1 and BRCA2 mutations among families with multiple affected cases with breast and/or 
ovarian cancer 
Reference Population No. of Selection Method Mutation frequency 
patients criteria  BRCA1
(%)
BRCA2
(%)
BRCA1/2
(%)
Europe        
   Thorlacius et al. 1996 Icelandic 21 ≥3 bc or ≥1
male bc 
F - 76 - 
   Håkansson et al. 1997 Swedish 56 ≥3 bc W 27 5 32 
   Vehmanen et al. 1997  Finnish 100 ≥3 bc or oc W 10 11 21 
   Lancaster et al. 1998 Welsh 17 ≥2 bc or oc W 35 12 47 
   Wagner et al. 1998 Austrian 81 ≥2 bc or oc W 21 - - 
   Wagner et al. 1999 Austrian 67 ≥2 bc or oc W - 9 - 
   Goelen et al. 1999 Belgian 42 ≥2 bc or oc W 24 10 33 
   Santarosa et al. 1999 Italian 57 ≥2 bc or oc W 16 21 37 
   Verhoog et al. 2001 Dutch 488 ≥ 2 bc or oc P + F 20 4 24 
   De La Hoya et al. 2002 Spanish 102 ≥3 bc or oc W 18 12 30 
   Meindl et al. 2002 German 250 ≥1 bc and ≥1 oc W 42 10 52 
   Meindl. et al. 2002 German 647 ≥2 bc W 12 8 21 
   Tereschenko et al. 2002 Russian 25 ≥2 bc or oc W 12 4 16 
   Perkowska et al. 2003 Polish 60 ≥2 bc or oc W 23 3 27 
        
North America        
   Rebbeck et al. 1996 US 23 ≥3 bc W 35 0 35 
   Serova et al. 1997 US 31 ≥3 bc W 19 26 45 
   Frank et al. 1998 US 238 ≥2 bc or oc W 27 13 40 
   Tonin et al. 1998 French Canadian 97 ≥3 bc or oc F 25 18 42 
   Martin et al. 2001 US 100 ≥1bc and ≥1 oc W 45 11 55 
        
South America        
   Ruiz-Florez et al. 2002 Mexican 19 ≥2 bc or oc W 0 0 0 
        
Asia        
   Ikeda et al. 2001 Japanese 113 ≥2 bc or oc W 13 19 32 
   Kang et al. 2002 Korean 21 ≥2 bc or oc W 24 19 43 
   Patmasiriwat et al. 2002 Thai 12 ≥2 bc or oc W 8 0 8 
   Zhi et al. 2002 Chinese 16 ≥2 bc W 6 0 6 
bc, breast cancer; oc, ovarian cancer, W, whole coding region; P, partial coding region; F, founder mutations 
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Mutation screening of BRCA1 and BRCA2 is challenging due to the wide mutation spectrum and 
large size of the genes. It is therefore not surprising that only a few studies have reported estimates 
of the mutation frequencies among unselected breast cancer patients. The largest studies have been 
carried out in Ashkenazi Jewish and Icelandic populations where individual, highly recurrent 
founder mutations have been found in 7-12% and 8-9% of unselected breast cancer patients, 
respectively (Johannesdottir et al., 1996; Thorlacius et al., 1997; Fodor et al., 1998; Warner et al., 
1999). The specific nature of such very recurrent founder mutations, and the presence of possible 
genetic or environmental modifying factors in those particular, isolated populations, mean that the 
results may not be used to estimate the contribution of BRCA1 and BRCA2 to breast cancer 
incidence in other populations. In some other reports patients have been unselected for family 
history, but the focus has been on early-onset disease (FitzGerald et al., 1996; Langston et al., 1996; 
Krainer et al., 1997; Malone et al., 1998; Hopper et al., 1999; Peto et al., 1999; Southey et al., 
1999). Mutation frequencies in these studies have varied from 1.9%-13% for BRCA1 and 2.2%-
2.7% for BRCA2. In a few studies where patients have been unselected both for family history and 
age at diagnosis the sample size has been quite small (130-211) and only BRCA1 has been analyzed 
(Newman et al., 1998; Tang et al., 1999). The mutation frequencies in these studies have varied 
between 1.4-3.8%. Taken together, in many populations the contribution of BRCA1 and BRCA2 to 
breast cancer burden remains to be determined.  
2.4.1.7. Identification of high-risk families 
Individuals with germline BRCA1 and BRCA2 mutations have a high lifetime risk of developing 
breast cancer, and an increased risk especially for ovarian but possible also to other cancers. As 
many of these diseases can be treated if diagnosed early enough, it is important to identify persons 
that are at high risk of carrying a predisposing mutation. Identification of such individuals enables 
the utilization of the specific management strategies that have been defined for mutation carriers 
(Domchek et al., 2003). These include intensified screening programs, administration of tamoxifen, 
and use of oral contraceptives. More radical procedures are prophylactic mastectomy and 
oophorectomy. The removal of ovaries, which is indicated to all female mutation carriers after 
childbearing, is shown to reduce ovarian cancer incidence by more than 90% and breast cancer 
incidence by around 50% (Rebbeck et al., 1999b, 2002; Kauff et al., 2002).  
Screening of BRCA1 and BRCA2 is laborious, expensive, and emotionally stressfull for the families. 
It is therefore important to find the clinical risk factors that associate with a positive mutation status 
so that the screening could be directed to individuals and families with a high likelihood of carrying 
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a mutation. Besides improving management in individuals with identified mutation, the family 
members that test negative can be released from the greater-than-average cancer risk. Several 
models that estimate the probability of carrying a BRCA mutation have been derived. However, 
these are designed only for identifying BRCA1 carriers (Berry et al., 1997; Couch et al., 1997; 
Shattuck-Eidens et al., 1997), require information that may not be easily available (Berry et al., 
1997; Parmigiani et al., 1998; Chang-Claude et al., 1999), or are designed to estimate the 
probability that an Ashkenazi Jewish woman has inherited one of the founder mutations (Foulkes et 
al., 1999; Hodgson et al., 1999; Hopper & Jenkins, 1999). Despite their advantages, these models 
may not be applicable as such for identifying both BRCA1 and BRCA2 mutations, and the absence 
of relevant information may leave the models unused. There may also be population-specific 
modifying factors that might alter the family phenotype in different populations, resulting in the 
possible need for population-specific modifications of the models.  
As BRCA mutations are found in only a small proportion of breast cancer families, another type of 
models that estimate the breast cancer risk have been developed. These assess the absolute lifetime 
risk of developing breast cancer. Two most commonly used such models are the Claus (Claus et al., 
1994) and Gail (Gail et al., 1989) models. The former derives estimates solely on family history, 
whereas the latter utilizes information also on reproductive variables, atypical hyperplasia, and 
history of breast biopsies. 
2.4.1.8. Tumors arising in BRCA1 and BRCA2 mutation carriers 
Several distinctive histopathological features have been associated with breast tumors arising in 
patients with BRCA1 mutations, suggesting that the pathogenesis of these tumors may differ from 
that of sporadic cases. Breast tumors in BRCA1-carriers are highly proliferating, frequently 
aneuploid, poorly differentiated, have more nuclear pleomorphism, and show higher histologic 
grade and more lymphocytic infiltration than sporadic tumors (Marcus et al., 1996; Johannsson et 
al., 1997; the Breast Cancer Linkage Consortium, 1997; Armes et al., 1998; Noguchi et al., 1999). 
Overrepresentation of medullary or atypical medullary breast carcinomas is also frequently 
observed (Marcus et al., 1996; the Breast Cancer Linkage Consortium, 1997; Armes et al., 1998; 
Eisinger et al., 1998; Verhoog et al., 1998). Somatic p53 alterations and overexpression of p53 
protein are common in BRCA1-tumors, whereas they are more often negative for estrogen and 
progesterone receptor and show low expression of ERBB2 (Johannsson et al., 1997; Armes et al., 
1999; Noguchi et al., 1999; Lakhani et al., 2002). Interestingly, frequent allelic loss of  BRCA1 in 
BRCA2-associated tumors and vice versa has also been observed (Staff et al., 2001). In contrast to 
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tumors in BRCA1-carriers, BRCA2-associated breast tumors appear to be more heterogeneous and 
show no characteristic clinicopathological features compared to sporadic tumors (the Breast Cancer 
Linkage Consortium, 1997; Armes et al., 1999; Noguchi et al., 1999). Both BRCA1- and BRCA2-
associated cancers are diagnosed at younger age and include higher incidence of bilateral tumors 
than sporadic cases (Easton et al., 1993, 1995; Ford et al., 1994; Miki et al., 1994; Wooster et al., 
1994; Marcus et al., 1996; Johannsson et al., 1997; Verhoog et al., 1998; Noguchi et al., 1999; 
Hamann & Sinn, 2000). 
By using comparative genomic hybridization, Tirkkonen et al. (1997) observed that the total 
number of somatic genetic alterations in tumors from BRCA1 and BRCA2 carriers was nearly 
double of that seen in control tumors. This supports the proposed role of BRCA1 and BRCA2 in 
maintaining genomic integrity. However, the changes in BRCA1-tumors differed from those in 
BRCA2-tumors. In cDNA microarray analysis significant differences in gene expression profiles 
were observed between BRCA1-, BRCA2-, and sporadic breast tumors, further supporting the 
molecular difference between cancers with underlying germline BRCA1- and BRCA2-mutations as 
well as cancers without such mutations (Hedenfalk et al., 2001). 
2.4.1.9. Survival of patients with BRCA1 and BRCA2 mutations 
There appears to be a trend towards worse outcome in breast cancer patients with germline BRCA1 
mutations compared to sporadic controls, although the difference doesn’t reach statistical 
significance in all studies (Foulkes et al., 1997; Ansquer et al., 1998; Johannsson et al., 1998; 
Verhoog et al., 1998; Chappuis et al., 1999; Foulkes et al., 2000; Hamann & Sinn, 2000; Stoppa-
Lyonnet et al., 2000; Eerola et al., 2001b; Moller et al., 2002; Goffin et al., 2003). In BRCA2
carriers the prognosis does not seem to differ from that of patients with sporadic disease (reviewed 
in (Verhoog et al., 2000; Eerola et al., 2001b). Ovarian cancer patients with germline BRCA1 or 
BRCA2 mutations appear to experience better survival than women without a mutation, the affect 
which is suggested to be due to enhanced susceptibility to chemotherapy (Narod & Boyd, 2002 and 
refs. therein). 
2.4.1.10. BRCA1 and BRCA2 in sporadic breast cancer 
Soon after identification, it became evident that somatic mutations in neither BRCA1 nor BRCA2
play a major role in the tumorigenesis of sporadic breast cancer (Futreal et al., 1994; Lancaster et 
al., 1996; Miki et al., 1996; Teng et al., 1996). In subsequent years the observation has been 
confirmed, with reports on such acquired inactivating mutations being extremely rare (Weber et al., 
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1996; Papa et al., 1998; Khoo et al., 1999; van der Looij et al., 2000). Still, BRCA1 and BRCA2 may 
affect the pathogenesis of non-familial breast carcinoma through other, more indirect mechanisms. 
Both protein products may be subcellularly mislocalized into the cytoplasm, and thereby turned 
nonfunctional (Chen et al., 1995b; Spain et al., 1999). Marked reduction in BRCA1 expression level 
has also been observed in sporadic breast tumors (Thompson et al., 1995; Yoshikawa et al., 1999), 
with correlation to tumor-grade (Taylor et al., 1998; Wilson et al., 1999), proliferation (Jarvis et al., 
1998), and metastatic potential (Taylor et al., 1998; Seery et al., 1999). Possible mechanisms that 
may lead to low BRCA1 expression include LOH, promoter hypermethylation, regulation of protein 
stability, allele specific expression, p53 or ID4 mediated repression, activation of the negative 
regulatory site in the first intron, loss of activation by transcription factors, or activation of NBR2 
expression (reviewed in Mueller & Roskelley, 2002). In BRCA2, no methylation of the putative 
promoter region has been observed (Collins et al., 1997), but there are reports on frequent LOH 
(Cleton-Jansen et al., 1995; Beckmann et al., 1996; Hanby et al., 2000; Johnson et al., 2002). 
BRCA1 and BRCA2 may also themselves function normally in sporadic cancer, but mutations in 
other components in their pathways may lead to malignant transformation (Rahman & Stratton, 
1998). So far, the extent of which BRCA1 and/or BRCA2 contribute to the pathogenesis of sporadic 
breast cancer remains unclear. 
2.5. Li-Fraumeni syndrome 
2.5.1. Clinical features 
Li-Fraumeni syndrome (LFS) is a rare, dominantly inherited cancer predisposition syndrome 
characterized by multiple early-onset malignancies including bone and soft-tissue sarcomas, 
leukemias, and tumors of the breast, brain, and adrenal cortex. Breast carcinomas are numerously 
the most common neoplasms, but more rare tumors, especially early onset sarcomas or 
adrenocortical tumors, can be considered as indicative of the syndrome. LFS was first described 
already in 1969 on the basis of four families in which siblings or cousins were affected with soft-
tissue sarcoma during infancy or childhood (Li & Fraumeni, 1969). These families had a striking 
history of breast and other neoplasms as well as multiple primary tumors. The definition of a classic 
LFS was defined in 1988 by Li and co-workers (Li et al., 1988). According to this criterion, an LFS 
family should include a proband with a sarcoma diagnosed under the age of 45 years, a first-degree 
relative with any type of cancer before 45 years of age, and an additional first- or second-degree 
relative in the same lineage with either any cancer under the age of 45 years or a sarcoma at any 
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age. As more families were identified, it was noted that all kindreds with features of LFS did not 
fulfill the classical criteria precisely and were therefore termed Li-Fraumeni-like (LFL) families 
(Birch et al., 1994). LFL families were defined on the basis of a proband with any childhood 
carcinoma, or sarcoma, brain, or adrenocortical tumor diagnosed under the age of 45 years, one 
first- or second-degree relative with a typical LFS carcinoma at any age, plus a first- or second-
degree relative in the same lineage with any cancer under the age 60 years. Another group has 
independently defined LFL as a clustering of two different LFS-tumors diagnosed at any age in 
individuals who are first- or second-degree relatives (Eeles, 1995). The criteria by Birch et al. 
(1994) is more widely used, and is also used in this thesis. 
2.5.2. Major predisposing gene p53 
For many years, the genetic basis of LFS remained elusive, until in 1990 the occurrence of germline 
mutations in the p53 tumor suppressor gene was reported in six families (Malkin et al., 1990; 
Srivastava et al., 1990). Due to the rarity of the syndrome and high mortality of the individuals, a 
candidate gene strategy was applied instead of formal linkage analysis. p53 was chosen as an 
plausible candidate, because its inactivation had been shown in the sporadic forms of many cancers 
associated with LFS. p53 was originally identified in 1979 (Lane & Crawford, 1979; Linzer & 
Levine, 1979) and later mapped to chromosome region 17q13.1 (McBride et al., 1986). It comprises 
of 11 exons, first of which is non-coding. The protein is a 53kD nuclear phosphoprotein that is 
made of four distinct domains: an N-terminal transactivation domain, a central DNA-binding 
domain, a tetramerization domain, and a C-terminal regulatory domain (Arrowsmith & Morin, 
1996; Soussi & May, 1996). The p53 protein is a transcription factor constitutively expressed in 
most cell types. It is activated and stabilized in response to different forms of cellular stress via 
post-translational modifications and protein-protein interactions, after which it transactivates or 
transrepresses the genes involved in cell-cycle control, apoptosis, DNA repair, and the formation of 
blood vessels (reviewed in Vogelstein et al., 2000). Mutations in p53 result in defects in monitoring 
genome integrity and therefore failure to activate mechanisms that would allow DNA damage to be 
repaired or damaged cells to be eliminated. Due to the multiple roles of the wild-type p53 protein in 
controlling the cell cycle and proliferation, it has been termed as the “guardian of the genome” 
(Lane, 1992) 
p53 is often considered as a classical example of a tumor suppressor. However, LOH has been 
observed in only about 50% of tumors from patients with germline p53 mutations (Varley et al., 
1997c, 1999; Sedlacek et al., 1998), and there is also evidence of haplo-insufficiency 
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(Venkatachalam et al., 1998). And in contrast to other tumor suppressor genes where many of the 
mutations are nonsense or frameshift alterations leading to absent or truncated protein, most p53
mutations are missense changes. Some substitutions also result in the gain-of-function activity, 
which can promote transformation and carcinogenesis even in the presence of a wild-type allele 
(Finlay et al., 1989; Dittmer et al., 1993). In addition, certain p53 mutants demonstrate a dominant-
negative function by, for example, forming oligomeric complexes with the wild-type protein and 
thus blocking its normal functions (Milner & Medcalf, 1991). 
p53 is the most commonly mutated gene in human cancer, and it has been estimated that over 80% 
of sporadic tumors carry mutations in p53 or in pathways that directly regulate it (Lozano & 
Elledge, 2000). Since the identification of the causative link between p53 and LFS, numerous 
germline mutations have been identified (Olivier et al., 2002). Mutation spectrum of the inherited 
mutations resembles that of somatic ones in that it is widely spread throughout the gene, with a 
considerable clustering seen within the DNA binding domain. Codons representing mutational hot 
spots in sporadic tumors (175, 245, 248, 273) are also more frequently mutated in the germline 
(Varley et al., 1997a; Olivier et al., 2002). However, as only the conserved exons 5-8 have been 
analyzed in many of the studies, the spectrum of mutations may be broader than initially estimated. 
In a study by Varley et al. (1997b) where the whole coding sequence, splice junctions, and the 
promoter region were screened, 26% of mutations were actually outside these exons.  
The presence of germline p53 mutations has also been analyzed in individuals with component 
tumors of LFS. Such mutations have been identified in the vast majority of patients with childhood 
adrenocortical carcinoma (Sameshima et al., 1992; Wagner et al., 1994; Varley et al., 1999; Ribeiro 
et al., 2001) and approximately 10% of patients with brain tumors (Kyritsis et al., 1994; Chen et al., 
1995a) or children with rhabdomyosarcoma (Diller et al., 1995). In contrast, adults with familial, 
early-onset, or bilateral breast cancer do not have germline p53 mutations to any significant degree. 
Börresen and co-workers (1992) found only one mutation among 40 early-onset breast cancer 
patients, and in a study by Sidransky et al. (1992) the frequency was even lower, 1/126. Both of 
these patients showed a very strong family history of cancer. When analyzing 167 unselected breast 
cancer patients only one mutation carrier with a positive family history was identified (Börresen et 
al., 1992). In studies where breast cancer patients with a positive family history (Prosser et al., 
1991; Börresen et al., 1992; Warren et al., 1992; Zelada-Hedman et al., 1997; Lehman et al., 2000; 
Balz et al., 2002) or bilateral disease (Lidereau & Soussi, 1992) have been analyzed, no coding 
region mutations have been identified. Additional reports on constitutional p53 mutations have been 
isolated case-reports on families with breast and ovarian cancer (Prosser et al., 1992; Jolly et al., 
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1994; Cornelis et al., 1997) or late-onset breast cancer (Sun et al., 1996). In Finland, germline p53
mutations have been identified in a small proportion of breast cancer families also meeting the 
LFS/LFL criteria (Huusko et al., 1999; Rapakko et al., 2001).  
Altogether germline p53 mutations have been identified in approximately 70% of LFS and 25% of 
LFL families (Eng et al., 1997; Varley et al., 1997b). This leaves one third of LFS and the majority 
of LFL families without detectable germline p53 mutations. Even if some mutations may have been 
missed due to location in non-coding or in the promoter regions, and some families may be due to 
chance clustering of sporadic cancer cases, other susceptibility gene(s) in the etiology of the 
syndrome are very likely. 
2.5.3. CHEK2, a new gene for Li-Fraumeni syndrome? 
2.5.3.1. Structure and expression  
Checkpoint kinase 2 (CHEK2, also known as CHK2) is a human homolog of the Saccharomyces
cerevisiae Rad53 and Schizosaccharomyces pombe Cds1 protein kinases that have crucial roles in 
controlling cell-cycle checkpoints after DNA damage and stalled replication (Matsuoka et al., 1998; 
Blasina et al., 1999; Brown et al., 1999; Chaturvedi et al., 1999). It is located on chromosome 
region 22q12, and its 14 exons encode a protein of 543 amino acids (Matsuoka et al., 1998). The 
CHEK2 protein has three functional domains; an N-terminal regulatory region with several serine-
glutamine and threonine-glutamine (SQ/TQ) pairs, a forkhead-associated (FHA) domain that 
mediates multiple protein-protein interactions, and a large C-terminal kinase domain (Matsuoka et 
al., 1998; figure 2). CHEK2 is a stable, predominantly nuclear protein that is expressed in a wide 
variety of human tissues (Matsuoka et al., 1998; Lukas et al., 2001). Interestingly, it may become 
activated in all phases of cell cycle as well as in quiescent and terminally differentiated cells (Lukas 
et al., 2001).  
Figure 2. The CHEK2 protein structure. Functional domains and structural motifs are shown with boxes, and 
the important phosphorylation sites are indicated below the protein. See text for details. 
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2.5.3.2. Function  
Following DNA damage or replication block, CHEK2 becomes activated through phosphorylation 
at multiple sites within the SQ/TQ rich region (Ahn et al., 2000; Matsuoka et al., 2000; Melchionna 
et al., 2000).  The phosphorylation is mediated by ATM after ionizing radiation (IR) (Ahn et al., 
2000; Matsuoka et al., 2000; Melchionna et al., 2000), whereas after ultraviolet irradiation or 
hydroxyurea treatment the responsible kinase is probably ATR (Matsuoka et al., 2000). The 
substrate specificities of ATM and ATR are thought to be distinct but overlapping, leading to 
potential partial functional overlap. The major site of phosphorylation is threonine (Thr) 68 (Ahn et 
al., 2000; Matsuoka et al., 2000; Melchionna et al., 2000). In order to be fully activated, 
autophosphorylation of Thr383 and Thr387 in the activation loop of the kinase domain is also 
required (Lee & Chung, 2001). This is probably achieved through Thr68 phosphorylation dependent 
homo-oligomerization and trans-autophosphorylation (Ahn et al., 2002; Xu et al., 2002).  
When activated, CHEK2 propagates the checkpoint signal to several different pathways that 
eventually lead to cell-cycle arrest in the G1/S, S, and G2/M phases, activation of DNA repair, and 
apoptosis (reviewed in Bartek et al., 2001). Downstream targets so far identified include BRCA1, 
p53, and members of the CDC25 family of phosphatases. The CHEK2 regulates the function of 
BRCA1 by phosphorylating it in Serine 988 and thereby releasing it from the complex with CHEK2 
itself (Lee et al., 2000). This phosphorylation is also important for the function of BRCA1 in the 
DNA damage response. By phosphorylating p53 CHEK2 stabilizes and activates this 
multifunctional tumor suppressor that in turn activates or represses several downstream targets 
involved in controlling G1/S and G2/M checkpoints, DNA repair, and apoptosis (Chehab et al., 
2000; Hirao et al., 2000; Shieh et al., 2000). Reciprocally, the CHEK2 expression is negatively 
regulated by functional p53, suggesting that the roles of CHEK2 and p53 may be partially 
complementary in controlling the cell cycle after DNA damage (Tominaga et al., 1999). Some 
contradictory results on p53 activation have also been obtained (Ahn et al., 2003; Jallepalli et al., 
2003). The observed discrepancies may reflect differences between study designs or specific cell or 
tissue types, variable responses of CHEK2 and p53 to various types of cellular stress, or the partly 
complementary functions of CHEK2, p53, and possibly CHEK1 and other proteins in DNA damage 
responses (Bartek & Lukas 2003). Besides through the proposed p53 activation, CHEK2 monitors 
the G2/M checkpoint by phosphorylating CDC25C; this phosphorylation creates binding sites for 
14-3-3 proteins, and the subsequent binding prevents CDC25C from activating CDC2, a protein 
kinase that regulates entry into mitosis (Peng et al., 1997; Matsuoka et al., 1998). In response to IR, 
CHEK2 mediates the degradation of another CDC25 phosphatase, CDC25A, together with CHEK1 
(Mailand et al., 2000; Falck et al., 2001b; Sörensen et al., 2003). This leaves CDK2 in a persistantly 
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phosphorylated state, which in turn leads to blockage of DNA replication. Besides nonfunctional 
cell-cycle arrest, malfunction of this pathway results to radioresistant DNA synthesis, an inability of 
cells to reduce the rate of replication when exposed to IR (Falck et al., 2001b). In addition to 
CDC25A regulation, CHEK2 controls the S-phase checkpoint through association with MDC1 (Lou 
et al., 2003). CHEK2 have a role also in radiation induced apoptosis, either through p53- (Hirao et 
al., 2000, 2002; Jack et al., 2002), MDC1- (Lou et al., 2003), or PML- (Yang et al., 2002b) 
pathways. Interestingly, CHEK2 activation has also been observed in human heart failure, where it 
may be involved in telomere dysfunction induced apoptosis of myocardial cells (Oh et al., 2003). 
Multiple functions of CHEK2 in maintaining genomic integrity after DNA damage are illustrated in 
figure 3. 
Figure 3. CHEK2 participates in multiple fundamental cellular processes. Modified from Bartek & Lukas, 
2003.
2.5.3.3. CHEK2 and cancer  
Central role of CHEK2 in controlling the cell cycle after DNA damage, a position in the middle of a 
pathway that is frequently targeted in cancer, and regulation of many tumor suppressors makes it an 
intriguing candidate for being a tumor suppressor itself. And indeed, in 1999, Bell and co-workers 
reported on germline CHEK2 mutations in LFS and LFL families (Bell et al., 1999). The Ile157Thr 
CHEK2
CDC25A
CDC25C
p53
PLK3
Damage-induced
transcription
DNA repair
PML E2F1
BRCA1
Apoptosis
MDC1
Cell cycle
arrest/ delay
27
variant resides in the FHA domain of the gene, and was found in a patient with three primary 
tumors (early-onset breast carcinoma, melanoma, and lung cancer). The other mutation, 1100delC,  
leads to a premature stop at codon 381, and was found in a typical LFS family with several cases of 
sarcomas, breast carcinomas, and brain tumors. Additional missense change (Arg145Trp) was 
observed in a colon cancer cell line. Despite the finding that one additional mutation in LFL-family 
was found to locate in one of the several copies that the 3’ end of the gene has throughout the 
genome (Bell et al., 2000; Sodha et al., 2000), these results suggest that CHEK2 may confer 
predisposition to many cancer types. Somatic mutations that have been observed in various sporadic 
tumors, including osteosarcomas, ovarian and lung tumors, lymphoid malignancies, vulval 
neoplasia, and myelodysplastic syndrome (Haruki et al., 2000; Hofmann et al., 2001; Tavor et al., 
2001; Miller et al., 2002; Reddy et al., 2002), support the role of CHEK2 in tumorigenesis. Altered 
expression has been observed in invasive testicular cancer, gastric carcinoma, and Non-Hodgkin’s 
lymphoma (Bartkova et al., 2001; Shigeishi et al., 2002; Tort et al., 2002). Interestingly, by age one 
year, Chek2-/- mice had not developed tumors of any kind (Hirao et al., 2002). 
2.5.4 CHEK1 and other plausible susceptibility genes 
Another putative gene behind LFS is CHEK1 (also known as CHK1), a human homologue of the 
Schizosaccharomyces pombe Chk1 checkpoint kinase. Following DNA damage, Chek1 becomes 
activated by ATR and BRCA1 through phosphorylation (Liu et al., 2000; Yarden et al., 2002). 
CHEK1 then phosphorylates CDC25A, B and C (Peng et al., 1997; Sanchez et al., 1997; Sörensen 
et al., 2003), eventually leading to the arrest of several stages of the cell cycle. Also p53 becomes 
phosphorylated and thereby activated and stabilized by the CHEK1 protein (Shieh et al., 2000). 
Interestingly, CHEK1 is also downregulated by p53 following reduction in CHEK1 mRNA 
accumulation suggesting that p53 and CHEK1 may play interdependent and complementary roles in 
regulating both the arrest and resumption of G2 checkpoint after DNA damage (Gottifredi et al., 
2001). Inactivating CHEK1 mutations may inhibit the phosphorylation of the target proteins after 
DNA damage or replication block, compromising the p53 apoptotic activity or the CDC25-
mediated delay in cell cycle.  
Chek1
-/- mice embryos exhibit gross morphological nuclear abnormalities, which result in early 
embryonic death (Liu et al., 2000; Takai et al., 2000). This indicates an essential role for Chek1 in 
cell growth, differentiation, and survival already at an early state of development. In WNT-1 
transgenic mice heterozygous Chek1 mutations enhance tumor formation, directly implying an 
involvement of the Chek1 pathway in tumor suppression (Liu et al., 2000). In humans, somatic 
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CHEK1 mutations have been identified in stomach, colorectal, and endometrial tumors (Bertoni et 
al., 1999; Menoyo et al., 2001). A shorter, tumor specific isoform lacking part of the kinase domain 
as well as a germline variant with a possible role in tumorigenesis have also been reported in small 
cell lung cancer (Haruki et al., 2000). In a first analysis of CHEK1 in LFS, no mutations were found 
in four LFS and 18 LFL-families (Bell et al., 1999). 
Besides p53, CHEK2, and CHEK1, germline mutations in LFS and LFL families have been looked 
for in tumor suppressors PTEN (Burt et al., 1999; Brown et al., 2000), Bcl10 (Stone et al., 1999), 
and CDKN2 (Burt et al., 1999; Portwine et al., 2000), but no mutations have been detected in any of 
these genes.  
2.6. Breast cancer as part of other hereditary cancer predisposition 
syndromes 
Breast carcinomas are component tumors also in other inherited cancer predisposition syndromes. 
Germline mutations in predisposing genes are, however, very rarely seen in breast cancer patients 
without manifestations of other features of the syndromes, and their contribution to familial 
aggregation of site-specific breast cancer, if any, is marginal. Four such syndromes are presented in 
the following. Additional work is required on familial melanoma and the gene behind it, CDKN2A,
as over-representation of breast tumors has been observed in families with a germline CDKN2A
mutation (Borg et al., 2000). Increased breast cancer risk has also been observed in a subset of 
families with hereditary prostate cancer (Grönberg et al., 2000), although the observation has not 
been confirmed in other studies (Isaacs et al., 1995; J Schleutker, personal communication). 
2.6.1 Ataxia-telangiectasia 
Ataxia-telangiectasia (AT) is a rare autosomal recessive disorder characterized by progressive 
neuronal degeneration, immunodeficiency, hypersensitivity to ionizing radiation, and an increased 
incidence of malignancies, especially of lymphoid origin. AT is caused by mutations in both alleles 
of the ATM gene (Savitsky et al., 1995). ATM encodes a large serine/threonine kinase that has a 
crucial role in signaling the presence of DNA DSBs. The protein also regulates several tumor 
suppressors, including p53, BRCA1, and CHEK2 (Banin et al., 1998; Canman et al., 1998; Khanna 
et al., 1998; Matsuoka et al., 1998, 2000; Cortez et al., 1999). Heterozygotes for ATM appear 
clinically normal, but are shown to have an excess risk of developing cancer, particularly female 
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breast cancer (e.g. Swift et al., 1987, 1991; Pippard et al., 1988; Borresen et al., 1990; Athma et al., 
1996; Janin et al., 1999; Olsen et al., 2001). Heterozygous mutations have been identified among 
breast cancer patients outside the context of AT as well, with growing evidence that in contrast to 
AT itself where truncating mutations are the most common, especially missense substitutions as 
well as in-frame deletions and splicing variants are those that mainly contribute to breast cancer 
predisposition (FitzGerald et al., 1997; Izatt et al., 1999; Broeks et al., 2000; Chenevix-Trench et 
al., 2002; Maillet et al., 2002). Depending on the assessed increase in the relative breast cancer risk 
(2.5 to 8-fold) and the frequency of heterozygotes in the population (0.5 to 1.5%), 1-2% up to 8% of 
breast cancer cases have been estimated to be attributable to ATM (Swift et al., 1987; Easton, 1994; 
Athma et al., 1996; Olsen et al., 2001). In the Nordic countries, approximately 1.4%, or 200 cases 
annually, are estimated to result from heterozygous ATM mutations (Olsen et al., 2001). Some 
contribution to familial aggregation is also suggested, as three of the 162 Finnish breast cancer 
families showed heterozygous germline ATM mutations (Allinen et al., 2002).  
2.6.2. Cowden’s disease 
Patients with Cowden’s disease (CD) develop hamartomas and benign tumors in multiple organs 
(e.g. skin, intestine, breast, and thyroid), and have an increased risk for carcinomas of the breast, 
thyroid, and endometrium. The lifetime risk for developing breast cancer is estimated to be 25-50% 
(Eng, 2003). Affected women develop also exuberant breast disease, and frequently report a history 
of multiple breast biopsies prior to the development of breast cancer (Brownstein et al., 1978; 
Schrager et al., 1998). The mode of inheritance is autosomal dominant, with high penetrance. The 
gene for CD, PTEN (also known as MMAC1 or TEP1) (Liaw et al., 1997), is a tumor suppressor 
that was simultaneously cloned by three groups (Li & Sun, 1997; Li et al., 1997; Steck et al., 1997). 
It was the first phosphatase known to act as a tumor suppressor. Germline PTEN mutations have 
been looked for in breast cancer patients with no manifestations of CD, but no disease-associated 
mutations have been detected (Tsou et al., 1997; FitzGerald et al., 1998; Carroll et al., 1999; Lauge 
et al., 1999). Outside the context of CD, germline PTEN mutations have been identified in 5% of 
patients with multiple primary neoplasms (De Vivo et al., 2000). Somatic PTEN mutations have 
been described in a wide variety of human tumors, especially those of endometrium, brain, prostate 
and kidney (Ali et al., 1999 and refs. therein). Of interest, only a low frequency of somatic 
mutations was seen in breast and thyroid carcinomas, two of the most common malignancies 
associated with CD. 
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2.6.3. Peutz-Jeghers syndrome 
Another rare, autosomal dominant cancer predisposition syndrome is a Peutz-Jeghers syndrome 
(PJS). Typical features of PJS are hamartomatous polyps in the gastrointestinal (GI) tract, and 
mucocutaneous melanin pigmentation of the lips, oral area, and digits. Germline mutations of the 
LKB1/STK11 gene, a serine/threonine kinase with a tumor suppressor function, have been shown to 
underlie PJS (Hemminki et al., 1998; Jenne et al., 1998). Patients with PJS appear to have a highly 
elevated risk for developing cancer, particularly of the GI tract, breast, pancreas, and gynecological 
sites (Giardiello et al., 2000 and refs. therein). In a meta-analysis an especially high relative risk of 
520 was observed for carcinoma of the small intestine, a malignancy otherwise very rarely seen 
(Giardiello et al., 2000). The highest cumulative risk of 54% was observed for breast cancer, with a 
relative risk of 15.2.  
2.6.4. Hereditary nonpolyposis colorectal cancer  
Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominantly inherited cancer 
syndrome caused by germline mutations in DNA mismatch repair (MMR) genes (reviewed in 
Peltomäki, 2003).  Defects in these genes cause microsatellite instability (MSI), a hallmark for 
HNPCC tumors. Besides colorectal cancer, also tumors of the endometrium, stomach, biliary tract, 
urinary tract, and ovaries are associated with HNPCC. The question as to whether the incidence of 
breast cancer is increased among families with HNPCC–syndrome remains controversial. In the 
early studies the positive association may have emerged partly from the rather loose criteria for 
HNPCC (Itoh et al., 1990; Nelson et al., 1993), allowing the inclusion of families that in fact belong 
to other cancer syndromes. No excess of breast cancer incidence was observed in a study of 1300 
high-risk members from 23 HNPCC families (Watson & Lynch, 1993). However, in 1996 a 
germline mutation in MLH1 gene was reported in a breast cancer patient from an HNPCC family, 
along with MSI as well as the loss of the wild-type allele in the breast tumor (Risinger et al., 1996). 
Later, Boyd et al. (1999) reported on a male HNPCC family member affected by breast cancer, who 
also had a MLH1 germline defect and whose tumor exhibited MSI and LOH. Despite the above-
mentioned reports, subsequent analysis have shown that MSI is a very rare phenomenon in breast 
tumors (Siah et al., 2000 and refs. therein). An association of breast cancer and HNPCC was again 
proposed by Scott et al. (2001), who reported a statistically significant over-representation of breast 
cancer in MLH1 mutation-positive families as well as in families with no detectable mutations. But 
again, in almost 200 Dutch HNPCC families the effect was not seen (Vasen et al., 2001).  In one 
recent study on the subject Müller et al. (2002), after finding no MSI in patients with both breast 
and colorectal cancer or breast tumors from MMR mutation carriers, conclude that although some 
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breast tumors may be associated with defects in MMR genes, breast cancer should not be 
considered as an integral malignancy of HNPCC. 
2.7. Search of additional susceptibility loci for hereditary breast 
cancer 
BRCA1 and BRCA2 explain only a small proportion of families with site-specific female breast 
cancer (Rebbeck et al., 1996; Hakansson et al., 1997; Schubert et al., 1997; Serova et al., 1997; 
Vehmanen et al., 1997a; Ford et al., 1998). Additional known susceptibility genes such as p53 and 
PTEN confer an increased risk, but mainly in the context of rare, stringently defined familial cancer 
syndromes. Therefore, additional predisposing genes are likely to exist. Positive linkage results 
have been obtained at chromosome region 8p12-p22 in French (Kerangueven et al., 1995) and 
German (Seitz et al., 1997), and at 13q21 in Nordic breast cancer families (Kainu et al., 2000). 
Large collaborative studies by the Breast Cancer Linkage Consortium were, however, unable to 
confirm these findings (Rahman et al., 2000; Thompson et al., 2002). This suggests that the positive 
results may represent differences between populations, family cohorts that have been collected 
using different ascertainment criteria, or just artefacts from the linkage analysis. Additional 
susceptibility locus at chromosome region 2q have been identified by genome-wide scan using 
Finnish site-specific breast cancer families (Huusko et al., 2003), but no gene at the region has as 
yet been discovered. Also candidate gene strategy has been applied, and there are reports on 
potential disease-associated germline mutations in genes like BACH1 (Cantor et al., 2001) and 
BARD1 (Thai et al., 1998; Ghimenti et al., 2002). Thus far these have been isolated findings and the 
importance of these genes in familial breast cancer remains to be elucidated. Recent segregation 
analyses have also revealed that besides residual dominantly inherited susceptibility, there appears 
to be recessively inherited susceptibility as well (Antoniou et al., 2001; Cui et al., 2001). 
Furthermore, a polygenic model has been proposed where several low-penetrance alleles may have 
multiplicative effect and account for a substantial proportion of the familial aggregation of breast 
cancer (Antoniou et al., 2001, 2002). 
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3. AIMS OF THE STUDY 
1. Little is known about the contribution of BRCA1 and BRCA2 to breast cancer incidence as most 
studies have focused on families with several affected family members, on highly recurrent 
founder mutations in isolated populations, or on young patients. In order to be able to better 
assess the load of germline BRCA1 and BRCA2 mutations on breast cancer in the Finnish 
population, we chose to analyze a large consecutive series of newly diagnosed breast cancer 
patients for all known Finnish BRCA1 and BRCA2 mutations (I).  
2. Breast cancer can often be treated if diagnosed early enough. It is therefore important to identify 
the families and individuals who are at high risk of carrying a mutation in a predisposing gene. 
When such families can be recognized, they can be offered genetic counseling and possibly also 
mutation testing. The purpose in study II was to identify clinical risk factors that associate with 
a positive mutation status, and to develop a model by which a probability of being a BRCA1 or 
BRCA2 mutation carrier can be evaluated for each family individually.  
3. Breast carcinoma is a main component tumor in hereditary multicancer Li-Fraumeni syndrome. 
Germline mutations in p53 gene predispose individuals to LFS, but such mutations cannot be 
found in all families. We wanted to further evaluate the molecular background of the syndrome 
and analyzed the role of p53 and its’ upstream regulators CHEK1 and CHEK2 in Finnish 
families with LFS, Li-Fraumeni-like syndrome LFL, and in families with phenotypical features 
of LFS (III).   
4. The only apparently deleterious germline CHEK2 mutation found in LFS and LFL families at 
the time, 1100delC, was observed in breast cancer patients in two different populations. 
Therefore, we assessed the role of CHEK2 in breast cancer by examining the frequency of the 
1100delC mutation in unselected breast cancer patients, in breast cancer families, and in healthy 
controls (IV).   
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4. MATERIALS AND METHODS
4.1. Subjects (I, II, III, IV) 
4.1.1. Unselected breast cancer patients (I, IV) 
In all, 1035 blood samples were collected from a consecutive series of newly diagnosed breast 
cancer patients who visited the Department of Oncology, Helsinki University Central Hospital 
(HUCH), between April 1997 and March 1998 (627 samples), or the Department of Oncology, 
Tampere University Central Hospital, during January 1997 through May 1999 (408 samples). The 
cohort covers 82% (87% in Helsinki and 75% in Tampere) of all breast cancer patients who visited 
the clinics during the study period. The two university hospitals accrue patients from a large, 
geographically defined region covering a large part of Southern Finland and account for about 30% 
of all breast cancer patients diagnosed in the country. Family history of breast, ovarian, and other 
cancers was obtained through a questionnaire, and patients reporting breast and/or ovarian cancer in 
first- or second-degree relatives were considered to have a family history of disease. The prevalence 
of the known Finnish BRCA1 and BRCA2 mutations in this cohort was analyzed in study I, and the 
frequency of the CHEK2 1100delC mutation in study IV.  
4.1.2. Breast cancer families (II, IV)  
Altogether 148 and 216 breast cancer families were included in studies II and IV in order to define 
the clinical characteristics that associate with a positive BRCA1 or BRCA2 mutation status, and to 
determine the frequency of the CHEK2 1100delC mutation, respectively. These families have 
three or more first- or second-degree relatives, including the proband, affected with breast or 
ovarian cancer. The families have been identified by patient interviews at the Department of 
Oncology, HUCH, as described by Eerola et al. (2000). Briefly, pedigrees were constructed as far 
back as the parents of the earliest breast or ovarian cancer generation, and information on all 
descendants was subsequently acquired. The genealogical data was confirmed through church 
parish registries and Population Register Center, and cancer diagnoses of the patients and all traced 
relatives, including those reported healthy, were confirmed through hospital records and/or Finnish 
Cancer Registry. In addition, 295 and 291 breast cancer patients with one first-degree relative 
affected with breast or ovarian cancer were analyzed in studies II and IV, respectively. The family 
history of these patients was based on information reported by the index patient. The patient cohort 
from which these small families were identified has been described by Eerola et al. (2000).  
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4.1.3. Families with Li-Fraumeni syndrome (III) 
Forty-four families that fulfilled the criterion for either LFS (3 families), extended LFL (7 families), 
or were phenotypically suggestive of LFS (34 families), were recruited through a systematic 
interview of breast cancer patients at the Departments of Oncology, HUCH, or patients seeking 
genetic counseling at the Department of Clinical Genetics, HUCH. More detailed description of the 
families with only phenotypical features of LFS is presented in study III. Information on family 
history of cancer was based on index patients’ reports, with subsequent confirmation of the 
diagnoses through hospital records or the Finnish Cancer Registry.
4.1.4. Healthy control individuals (III, IV) 
Blood samples from anonymous cancer-free individuals were kindly provided by the Department of  
Clinical Genetics, HUCH. These control individuals were used in study III to verify the nature and 
frequency of the previously unidentified sequence variants in p53, CHEK1, and CHEK2. In study 
IV, DNA or peripheral blood from 1885 healthy blood donors was obtained from the Finnish Red 
Cross Blood Transfusion Service. The samples were collected at eight regional centers around the 
country covering all geographical regions in Finland. This cohort was used to assess the frequency 
of the CHEK2 1100delC mutation in healthy population.  
4.2. DNA and RNA extraction (I, II, III, IV) 
Genomic DNA from peripheral blood lymphocytes was extracted by a standard phenol-chloroform 
method or by QIAamp DNA blood maxi-kit (Qiagen) (I, II, III, IV). In study III, DNA from 
paraffin-embedded tumor blocks was obtained by using QIAamp DNA mini-kit (Qiagen), and total 
cellular RNA from lymphoblastoid cell lines was extracted by using Rneasy mini-kit (Qiagen). 
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4.3. Mutation analysis (I, II, III, IV)
4.3.1. Screening of the known mutations (I, II, IV) 
4.3.1.1. Restriction fragment length polymorphism (RFLP) analysis (I, II) 
Whenever appropriate restriction enzyme was available the RFLP analysis was used to screen the 
known Finnish BRCA1 and BRCA2 mutations in unselected breast cancer patients (I), in 53 breast 
cancer families not belonging to the cohort of 95 families where complete mutation analysis of the 
whole coding regions and exon/intron boundaries have previously been performed (II) (Vehmanen 
et al., 1997a, b), and in 295 breast cancer patients with one affected first-degree relative (II). In 
brief, genomic DNA was amplified by PCR, the PCR products were digested with suitable enzyme 
according to conditions recommended by the manufacturers (New England Biolabs, MBI 
Fermentas, Promega), and digestion products were analyzed on a 3.5% ethidium bromide stained 
agarose gels. All RFLP analyses were designed so that the possibility of a false negative result was 
eliminated, i.e. there were always restriction sites besides the mutation position. Screened 
mutations, used enzymes, and digestion conditions are presented in table 5. 
4.3.1.2. Direct agarose gel electrophoresis (I, II) 
Mutations involving 5 or 11 base pair deletions (BRCA2, 999del5 and BRCA1, 5145del11) were 
screened by amplifying genomic DNA by PCR and running the PCR products directly on a 3% 
ethidium bromide stained agarose gel, with visualization under UV illumination.  
4.3.1.3. Allele specific oligonucleotide (ASO) hybridization (I, II)  
The ASO hybridization was used to screen the known Finnish BRCA1 and BRCA2 mutations if 
suitable restriction enzyme was not available (I, II). The protocol has been previously described by 
Friedman et al. (1995). In short, amplified PCR products were denatured, transferred to nylon filters 
(DuPont/NEN) using a 96-well dot-blot vacuum apparatus (Bio-Dot SF, Bio-Rad), and fixed under 
ultraviolet light. Two ASO probes were designed for each mutation, one for the wild-type sequence 
and another for the mutant sequence (table 5). The probes were end-labeled with [α–32P]dCTP 
(DuPont/NEN) using terminal transferase (Boehringer Mannheim) according to manufacturer’s 
instructions. Filters were prehybridized for 30-60 min at 54°C, incubated with the labeled probe for 
4 h at 54°C, and washed. The result was visualized by exposing the dried filters to X-ray films at  
–80°C for 4 h-over night. 
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Table 5. Known Finnish BRCA1 and BRCA2 mutations and the methods used to screen them in studies I and 
II.  
Gene and mutation Mutation type Screening method Restriction enzyme and  
digestion condition/ ASO probes 
BRCA1    
Ex11, 1924delA Nonsense RFLP Tsp509Ia, 65°C, over night 
Ex11, 2803delAA Frameshift ASO aagaaaca(aa)gtccaaaagt                              
Ex11, 3264delT# Frameshift ASO gaagtagg(t)tccagtacta 
Ex11, 3604delA Frameshift RFLP MboIIa, 37°C, 1  h 
Ex11, 3744delT Frameshift RFLP Tsp509Ia, 65°C, over night 
Ex11, 3904C→A Nonsense RFLP Tsp509Ia, 65°C, over night 
Ex11, 4153delA Frameshift RFLP MboIIa, 37°C, 1  h 
Ex12, 4216(-2)A→G Splice site RFLP MseIa, 37°C, over night  
Ex13, 4446C→T Nonsense ASO gaggacctg(c/t)gaaatcca 
Ex17, 5145del11 Frameshift Gel electrophoresis
Ex20, 5370C→T Nonsense ASO ggtccaaag(c/t)gagcaaga 
Ex20, 5382insC Frameshift RFLP BstOIc, 60°C, over night 
BRCA2 
Ex9, 999del5 Frameshift Gel electrophoresis
Ex11, 4081insA Frameshift ASO aagtgaaaa(a)aaataataa 
Ex11, 5797G→T Nonsense RFLP NlaIIIa, 37°C, over night 
Ex11, 6495delGCA→C Frameshift ASO tcagaactga(gca/c)tagtcttca 
Ex11, 6503delTT Frameshift RFLP MboIIa, 37°C, 1  h 
Ex15, 7708C→T Nonsense ASO caggatatg(c/t)gaattaag 
Ex18, 8555T→G Nonsense RFLP MseIa, 37°C, over night 
Ex24, 9346(-2)A→G Splice site RFLP BfmIb, 37°C, over night 
ex, exon; ASO, allele-specific oligonucleotide hybridization; RFLP, restriction fragment length polymorphism; 
manufactured by aNew England Biolabs, bMBI Fermentas, cPromega; #analyzed only in study II  
4.3.1.4. Minisequencing (IV) 
The minisequencing protocol described by Syvänen et al. (1993) was used to assess the frequency 
of the CHEK2 1100delC mutation in unselected breast cancer patients, breast cancer families, and 
healthy controls (IV). Briefly, genomic DNA was amplified with one normal and one biotinylated 
primer (5:1). The PCR product was then attached to the streptavidin coated microtitration well 
(Wallac) with biotin-streptavidin bond (1-1,5 h in rotation, RT). After the wash the other strand was 
removed by alkaline denaturation (50 mM NaOH, 5 min). Detection primers were applied to the 
wells with 3H-labelled nucleotides (Amersham Biosciences), and after the incubation (15 min, 
50°C) and wash the counts were measured by the β-rack (1450 Microbeta, Wallac). There were 
always two wells for each sample, the one for recognizing the normal and the other for recognizing 
the mutated nucleotide.  Nested PCR was used to detect the CHEK2 1100delC mutation; first PCR-
reaction to amplify chromosome 22 specific product (primers: 10FPF: TTAATTTAAGCAAAA 
TTAAATGTCC, 10RPR: GGCATGGTGGTGTGCATC) and the second to obtain short enough 
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product suitable for minisequencing (10BF-bio: GAAACTGATCTAGCCTAC, 10R: CAACAG 
AGCAAGACACATTTG). The minisequencing primer was TCTTGGAGTGC CCAAAATCA. All 
positive signals were verified by an independent PCR-amplification and detection method.  
4.3.2. Search for novel mutations (II, III) 
4.3.2.1. Protein truncation test (PTT) (II) 
Protein truncating mutations in large exons of BRCA1 and BRCA2 were screened by PTT in 36 
breast cancer families with an ovarian cancer case or a breast cancer patient diagnosed below 50 
years (II). Exons 11 of BRCA1 and BRCA2 were amplified in three and five overlapping fragments, 
respectively, and BRCA2 exon 10 as a single fragment using primers previously published 
(Hogervorst et al., 1995; Friedman et al., 1997; Hakansson et al., 1997). A coupled in vitro
transcription-translation reaction was carried out using the TNT?7 Coupled Reticulocyte Lysate 
(Promega) according to manufacturer’s instructions. Detection was based on [35S]-labelled 
methionine (Amersham Biosciences). Polypeptides were first run in a concentrating gel (5% 
polyacrylamide) for 1 h at 30 mA, and then in a separating gel (12.5% polyacrylamide) for 4 h at 50 
mA. After the run the gels were dried, and exposed to Biomax X-ray films (Kodak) for 2-72 h at  
–80°C. 
4.3.2.2. Conformation sensitive gel electrophoresis (CSGE) (III) 
Mutations in p53, CHEK1, and CHEK2 genes were searched for by CSGE (III) (modified from 
Ganguly et al., 1993; Couch et al., 1996). Genomic DNA was amplified by PCR, with reverse 
primers being labeled with [γ-33P]dATP (Amersham Biosciences) utilizing T4-polynucleotide 
kinase (New England Biolabs). The relation of unlabeled forward and reverse primers in the PCR 
reaction was 1:1, and in addition 1.5 x amount of labeled primer was used. PCR products were 
denatured for 10 min at 95°C, after which the PCR machine was switched off to allow the products 
slowly form heteroduplexes as they cooled to RT (45 min). Samples were run on mildly denaturing 
CSGE-gels (10% acrylamide, 10% ethylene glycol, 15% formamide) either at 35 W for 3-4 hours or 
at 3 W over night. The result was visualized by exposing the dried gels on Biomax X-ray films 
(Kodak) for 2-72 h at RT.  
Particular attention was paid when designing primers for the duplicated region of CHEK2 exons 10-
14. There, all homologous sequences obtained from the National Center for Biotechnology 
Information (NCBI) BLAST Server (www.ncbi.nlm.nih.gov/BLAST) were aligned, and primers 
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were designed to include at least a few nucleotide differences between the homologous copies and 
the actual CHEK2 sequence in chromosome 22. The primers were as follows: 10FPF: 
TTAATTTAAGCAAAATTAAATGTCC, 10RPR: GGCATGGTGGTGTGCATC; 11FPF: GTGCT 
GGGATTACAAGCCTA, 11RPR: TACATGATACTTAACCCTCAC; 12FPF: CTGTTAATTCT 
GGCATACTC, 12RPR: TTAGATTAAACACTCAACAAAG; 13FPF: TCAGGATCTTGGATAC 
TAATTA, 13RPR: TGCTGGAGCGAATCAAGTTA; 14FPF: CCCCACTTTACTGGAAGC, 
14RPR: TCTACAAAATATATAAAAATTAACA. 
4.3.3. Direct sequencing (I, II, III, IV) 
Direct sequencing was used to confirm positive results obtained in RFLP, ASO, agarose gel 
electrophoresis, or minisequencing, and to characterize aberrant band shifts observed in PTT or 
CSGE. Genomic DNA was first re-amplified, and PCR products were purified using the QIAquick 
PCR purification kit (Qiagen). Sequencing reactions were carried out for both forward and reverse 
orientations utilizing ABI PRISM dRhodamine Cycle Sequencing or BigDye Terminator kits 
(Applied Biosystems). The products were then run and analyzed on an ABI 310 Automated 
Sequencher (Applied Biosystems) according to manufacturer’s instructions.  
4.4. Haplotype analysis (III) 
A haplotype analysis was performed in study III to examine the possible founder effect in p53 and 
CHEK2. The polymorphic microsatellite markers were obtained from the NCBI UniSTS database  
(www.ncbi.nlm.nih.gov/Entrez/query.fcgi?db=unists) and for p53 were: D17S1810, D17S1823, 
D17S938, TP53, D17S1353, and D17S786; and for CHEK2 were: D22S1167, D22S1144, 
D22S275, and D22S280. Genomic DNA was amplified by PCR, with one of the primers being 
labeled with [γ-33P]dATP (Amersham Biosciences) utilizing T4- polynucleotide kinase (New 
England Biolabs). Denatured PCR products were then separated in a 10% mildly denaturing 
polyacrylamide gel, and the result was visualized by exposure on Biomax X-ray film (Kodak) for  
2 h at RT. 
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4.5. Immunohistochemical analysis (IV) 
Expression of the CHEK2 protein was analyzed by immunohistochemical staining of a tissue 
microarray including 124 breast tumors from BRCA1/2 mutation negative families (for tissue 
microarray construction, see Kononen et al., 1998). Both the antibody (mouse monoclonal DCS-
270 against human CHEK2) and its application in sensitive immunoperoxidase staining of human 
tissues have been previously described (Bartkova et al., 2001; Lukas et al., 2001). Briefly, the 
deparaffinized sections were boiled in a microwave for 10 min in citrate buffer (0.01M citric acid 
monohydrate, pH 6.0) to unmask the antigen. The sections were then incubated with primary 
antibody (4°C, over night), and the result was detected using sensitive immunoperoxidase staining 
(Vectastain Elite kit, Vector laboratories). To enhance sensitivity of the detection, the peroxidase 
reaction was enhanced with 3,3’-diaminobenzidine in 0.03% nickel sulphate as chromogen.  
Nuclear counterstaining was omitted for photography. Specificity and reproducibility were 
controlled by including DCS-270 preabsorbed with recombinant CHEK2 protein, analyzing two 
separate samples from each tumor, staining normal breast tissues simultaneously under identical 
conditions as well as comparing the areas of normal breast tissue present on the tissue array, and 
staining the array with an unrelated monoclonal antibody. The staining of tumors was considered 
aberrantly reduced when a considerably lower staining intensity was seen and/or if CHEK2 was 
detected in less than 50% of cancer cells. The staining results were evaluated without prior 
knowledge of the genetic status of CHEK2.
4.6. Statistical analysis (I, II, IV) 
4.6.1. Tests for statistical significance (I, II, IV) 
Fisher’s exact test or χ2 test (dichotomous variables), or Mann-Whitney test (continuous variables; 
SPSS version 8.0 for Windows) were used to determine statistical significance, when necessary (I, 
II, IV). All P values were two-sided. 
4.6.2. Logistic regression (II) 
Logistic regression with backward selection (99%) was used to calculate the logarithm of odds of 
carrying a germline BRCA1 or BRCA2 mutation as a linear function of the variables that were 
significant in the univariate analysis (II). The probability of a mutation was assessed by using the 
following equation:  
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p=eL/(1+eL),
where e is the exponential function and L is the log odds. L can be calculated with the formula L=α
+ β1V1 + β2V2 + …+ βkVk, where α is a constant from the equation, β1, β2, and … βk are the 
weighted values from the regression analysis, and V1, V2, and …Vk are the corresponding variables. 
4.6.3. Odds ratios (IV) 
In order to determine the magnitude of the elevated breast cancer risk in CHEK2 1100delC carriers, 
odds ratios were calculated by defining a cross-product ratio of the entries in the 2x2 table (ad/bc, 
where a=exposed with a disease, b=unexposed with a disease, c=exposed with no disease 
d=unexposed with no disease) (IV). 95% confidence intervals for the odds ratios were based on the 
natural logarithm of the odds ratios (ln(OR)-1.96se[ln(OR)], ln(OR)+1.96se[ln(OR)]), where se is a 
standard error. Standard error of the ln(OR) was defined as a square root of 1/a+1/b+1/c+1/d. 
4.7. Ethical issues 
Appropriate research permissions have been obtained from the Ethics Committees of the 
Departments of Obstetrics and Gynecology, and Oncology, HUCH, and the Ministry of Social 
Affairs in Finland. All patients and family members participating in the study signed an informed 
consent. Relatives were only contacted with the permission of the proband. No information on the 
mutation analyses was given to any patient or family member, but genetic counseling was offered to 
those with a suspected hereditary predisposition. 
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5. RESULTS 
5.1. Germline BRCA1 and BRCA2 mutations among unselected breast 
cancer patients (I) 
A total of 19 germline BRCA mutations were found among 1035 unselected breast cancer patients 
(1.8%), four in BRCA1 (0.4%) and 15 in BRCA2 (1.4%). Nine of the 11 recurrent mutations 
previously described in Finnish breast-ovarian cancer families were detected in altogether 17 
patients, and one previously unique mutation (BRCA2, 5797G→T) was found here in two patients. 
Detected mutations with clinical characteristics of the mutation carriers are presented in table 6. 
Table 6. BRCA1 and BRCA2 mutations among unselected breast cancer patients and personal and family 
history of breast and ovarian cancer of the mutation carriers 
Patient 
ID 
Gene and mutation Type of 
mutation 
Age at 
diagnosis
(y) 
No. of 1
st
 and 2
nd
 degree relatives 
with brca and ovca and their age 
at diagnosis (y) 
Index 
patient 
with brca 
<40 y 
(n=71)** 
Ovca in a 
family 
(n=40)** 
>2 brca 
cases but 
no ovca 
cases in a 
family  
(n= 82)** 
BRCA1       
K506 Ex11, 3604delA Frameshift 29 2 (brca 34, ovca 50) Yes Yes No 
K382 Ex12, 4216(-2)A→G Splice site 39 - Yes No No 
S4 Ex13, 4446C→T Nonsense 48 5 (brca 30, 40y; ovca 45, 45, 68) No Yes No 
P321 Ex20, 5370C→T Nonsense 71 4 (brca 46, 55, 55; ovca 50) No Yes No 
        
BRCA2       
K3 Ex9, 999del5 Frameshift 47 5 (brca 27, 33, 59, n.k.; ovca 65) No Yes No 
K82 Ex9, 999del5 Frameshift 57 2 (brca 52, 59) No No Yes 
P566 Ex11, 5797G→T Nonsense 30 1 (brca 58) Yes No No 
P067 Ex11, 5797G→T Nonsense 50 1 (brca n.k.) No No No 
K179 Ex11, 6503delTT Frameshift 56 2 (brca 71, n.k.) No No Yes 
464 Ex15, 7708C→T Nonsense 36 6 (brca 34, 42, 45, 61, 95; ovca 47) Yes Yes No 
P013 Ex15, 7708C→T Nonsense 37 5 (brca 34/40y§, 34, 38, 54; ovca 46) Yes Yes No 
P179 Ex15, 7708C→T Nonsense 32 2 (brca 49; ovca n.k.) Yes Yes No 
P625 Ex15, 7708C→T Nonsense 34 1 (brca 55) Yes No No 
P563 Ex15, 7708C→T Nonsense 61 2 (brca 38, 43) No No Yes 
P360 Ex18, 8555T→G Nonsense 59 2 (brca 50; ovca 60y#) No Yes No 
K79 Ex24, 9346(-2)A→G Splice site 50 2 (brca 33, 65) No No Yes 
K106 Ex24, 9346(-2)A→G Splice site 56 - No No No 
P342 Ex24, 9346(-2)A→G Splice site 71 - No No No 
K323 Ex24, 9346(-2)A→G Splice site 73 - No No No 
7/19(37%) 8/19(42%) 4/19(21%) 
*y, years; brca, breast cancer; ovca, ovarian cancer; n.k., not known; **n=181 for patients belonging to any of the three subgroups; 
§bilateral breast cancer; #index case diagnosed with breast cancer at age 59 years and with ovarian cancer at 60 years 
The strongest predictor of a mutation was a positive family history of ovarian cancer. Only 40 
patients (3.9% of all patients) reported a relative affected with ovarian cancer, but this small 
subgroup accounted for 42% (8/19) of mutations found in the entire study population, including 
three out of four BRCA1 mutations. Twenty percent of all patients with a family history of ovarian 
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cancer, irrespective of family history of any other cancers, were mutation positive. Of nine patients 
belonging to large breast-ovarian cancer families (three or more affected) five (56%) carried a 
mutation. Observed mutations in different subgroups defined by family history of breast and 
ovarian cancer are presented in table 7.  
Table 7. BRCA1 and BRCA2 mutations in different subgroups according to family history of breast and 
ovarian cancer. 
Affected relatives with  No. of cases No. with a mutation Mutation 95% CI
a
 P value
b
breast and ovarian 
cancer 
tested BRCA1 BRCA2 BRCA1/2 frequency 
(%)
None 677 1 3 4 0.6 0.2-1.5 
       
One 256 0 4 4 1.6 0.4-4.0 .23 
Breast cancer 236 0 3 3 1.3 0.3-3.7 .38 
Ovarian cancer 20 0 1 1 5.0 0.1-24.9 .14 
        
Two 78 1 5 6 7.7 2.9-16.0 <.0005 
Breast cancer only 67 0 4 4 6.0 1.7-14.6 .003 
Breast and ovarian cancer 11 1 1 2 18.2 2.3-51.8 .003 
        
Three or more 24 2 3 5 20.8 7.1-42.2 <.0005 
Breast cancer only 15 0 0 0 0 0-21.8 1.0 
Breast and ovarian cancer 9 2 3 5 55.6 21.2-86.3 <.0005 
        
Total 1035 4 15 19 1.8 1.1-2.9  
aCI, confidence interval; btwo-sided P value compared with the group with no family history 
Another indicator of a mutation was early age of breast cancer onset. In the cohort of 1035 patients 
71 were diagnosed below age 40 years, and seven of these carried a mutation (9.9%). This mutation 
frequency is eight times higher than in patients diagnosed at 40 years or older (9.9% versus 1.2%; 
P<0.0005). Most young mutation positive patients had a family history of at least breast cancer, but 
one carrier diagnosed at age 39 years didn’t report any cancer cases in a family. Mean age at 
diagnosis of the mutation positive patients was 49.7 years (47.0 for BRCA1 mutation carriers and 
50.5 years for BRCA2 carriers), compared to 57.5 years among patients with no mutations 
(P=0.026). The two groups mentioned above, patients with a family history of ovarian cancer or 
early age of breast cancer onset (105 patients, 10.1% of all), accounted for 11 of the 19 mutations 
(58%).  
Family history of site-specific breast cancer was not strongly predictive of a mutation. The mutation 
frequency among 318 patients with at least one relative with breast cancer was only 2.2%. This is 
not significantly different from the overall mutation frequency of 1.8% in the entire study group. 
However, among 82 patients with two or more relatives with breast cancer but no ovarian cancer, 
four (4.9%; 95% CI 1.3 - 12.0) were mutation positive. These four patients would not have been 
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found by the other two criteria (ovarian cancer, early-onset breast cancer). No mutations were found 
in the 15 largest site-specific breast cancer families with four or more affected relatives (table 7).  
Finally, there were 677 patients with no family history of breast or ovarian cancer. BRCA1 or 
BRCA2 mutations were detected in four (0.6%) of them, three of whom were older than 40 years at 
the time of diagnosis. One additional mutation positive patient had one relative affected with breast 
cancer, but neither the patient, nor the relative was known to be diagnosed under 40 years of age.  
5.2. BRCA1 and BRCA2 germline mutations among breast and breast-
ovarian cancer families (II) 
Among 148 families with three or more first- or second-degree relatives affected with breast or 
ovarian cancer a total of 29 germline BRCA mutations were identified (16.9%), 16 in BRCA1
(10.8%) and 13 in BRCA2 (8.8%). In addition to mutations formerly detected in Finland, two new 
nonsense mutations were identified  (BRCA1, 1806 C→T and BRCA2, 5797 G→T). The former of 
these has been found in many other populations, and also the latter one has recently been detected 
among Western Europeans (the BIC database). Both mutations were also found in other Finnish 
breast (study I) and/or ovarian (Sarantaus et al., 2001a, b) cancer families. All in all, the vast 
majority (24/29) of mutation carriers was found to harbor one of the founder mutations, and only 
five had unique mutations not detected thus far in Finland.  
The mean age at diagnosis in the mutation positive families was 41,6 years and in the mutation 
negative families 51,4 years (P<0.001). Of the 52 families with at least one patient diagnosed under 
the age of 40, 20 (38%) were found mutation positive. Ovarian cancer was present in 48 families, of 
which 24 (50%) carried a mutation. Twenty families had both ovarian cancer and a breast cancer 
patient diagnosed before age 40 years, and 16 (80%) of these were found to carry a mutation. Of the 
100 families with site-specific breast cancer only five carried a mutation (5%), and mutations were 
lacking altogether in 21 families with four or more cases of breast but no ovarian cancer or young 
breast cancer patient (diagnosis below 40 years). All families classified by the presence of ovarian 
cancer and a breast cancer patient diagnosed under the age of 40 years are presented in table 8. 
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Table 8.  BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families.
                  Number of mutationsFamily history of breast and 
ovarian cancer  
Number of 
families studied BRCA1 BRCA2 No mutations 
Mutation  
frequency 
(%)
3 affected 74 6 2 66 10.8
   only breast, none under 40 years 47 0 1 46 2.1
   only breast, some under 40 years 15 1 0 14 6.7
   breast and ovarian, none under 40 years 9 3 0 6 33.3
   breast and ovarian, some under 40 years 3 2 1 0 100
4 affected 35 5 3 27 22.9
   only breast, none under 40 years 15 0 0 15 0
   only breast, some under 40 years 7 1 0 6 14.3
   breast and ovarian, none under 40 years 11 3 1 7 36.4
   breast and ovarian, some under 40 years 3 1 2 0 100
≥5 affected 39 5 8 26 33.3
   only breast, none under 40 years 6 0 0 6 0
   only breast, some under 40 years 10 0 2 8 20.0
   breast and ovarian, none under 40 years 9 1 0 8 11.1
   breast and ovarian, some under 40 years 14 4 6 4 71.4
Total 148 16 13 119 19.6
   only breast, none under 40 years 68 0 1 67 1.5
   only breast, some under 40 years 32 2 2 28 12.5
   breast and ovarian, none under 40 years 28 7 1 20 28.6
   breast and ovarian, some under 40 years 20 7 9 4 80.0
Only one mutation (BRCA2, 7708C→T) was found among 295 breast cancer patients with just one 
affected first-degree relative (0.3%). In this family the proband had been diagnosed at the age of 37 
years, and her mother had deceased of breast cancer at the age of 40 years. Altogether, there were 
26 patients diagnosed under the age of 40 years, and only one of these carried a mutation (3.8%). 
Ovarian cancer was present in 14 families, but no mutations were found among these. In total, 
ovarian cancer patient or a young breast cancer patient diagnosed under 40 years was present in 39 
families, but among these only one mutation was found (2.6%). 
5.3. Probability model for identifying families with germline BRCA1
and BRCA2 mutations (II) 
Possible associations between specific familial characteristics and the presence of a BRCA1 or 
BRCA2 germline mutation was examined in 148 previously described families (5.2.) using 
univariate and multivariate analyses. All variables tested in the univariate analysis and the observed 
associations are shown in table 9. Variables that were predictive of a mutation in the univariate 
analysis were used in the multivariate analysis (stepwise backwards logistic regression, 99%), in 
which only two variables were still significant: the number of ovarian cancer cases in a family and 
the age at diagnosis of the youngest breast cancer patient. Based on these a probability model for 
harboring a deleterious mutation was devised, and can be written in the form of: 
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                                               p  =  eL / (1 + eL)
and L can be calculated from the equation L = 2.87 + (-0.14) x V1+ 2.11 x V2
where 2.87 is a constant and -0.14 and 2.11 are the coefficients received from the regression 
analysis, V1 is the age of the youngest breast cancer patient in a family, and V2 is the number of 
ovarian cancer cases in a family. 
Table 9. Tested variables and observed associations in univariate analysis. 
BRCA1/BRCA2
(n=29) 
Non-BRCA1/2
(n=119) 
P value 
Variables regarding the number of breast and ovarian cancer cases Mean number of cancer cases  
     Mean number of breast cancer cases in a family 3.5 3.8 0.304 
     Mean number of ovarian cancer cases in a family 1.4 0.2 <0.0005 
     Mean number of bilateral breast cancer cases in a family 0.5 0.3 0.292 
Variables regarding the age at diagnosis Age (years)  
     Mean age at diagnosis of the index cases 41.3 51.4 <0.0005 
     Mean age at diagnosis of the youngest breast cancer patients 38.5 46.0 <0.0005 
     Mean age at diagnosis of the youngest ovarian cancer patients 52.0 59.7 0.056 
     Mean age at diagnosis of the breast cancer cases 47.6 56.4 <0.0005 
Variables regarding the presence of various cancer types Proportion  
     Presence of ovarian cancer in a family 79% 20% <0.0005 
     Presence of breast and ovarian cancer in a same woman 34% 2.5% <0.0005 
     Presence of bilateral breast cancer in a family 31% 24% 0.482 
     Presence of prostate cancer in a family 24% 15% 0.272 
Ninety-seven percent (28/29) of the mutation carrier families obtained a probability greater than an 
arbitrary cut off value of 10%. The mean probability for mutation positive families was 55%, and 
for mutation negative families 11%. Altogether, 63 of the 148 study families (43%) obtained 
probabilities over 10%, and 28 of these (44%) carried a mutation.  
In order to assess how well the two models originally designed for identifying probable BRCA1
carriers (Couch et al., 1997; Shattuck-Eidens et al., 1997) fit for the identification of mutations in 
both genes, probabilities were determined for each family by using these models as well. All 
mutation positive families with detailed information on family history of cancer, ages at diagnosis, 
and probabilities of being a mutation carrier according to our model and models developed by 
Shattuck-Eidens et al. (1997) and Couch et al. (1997) are presented in table 10. 
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Table 10. Families with BRCA1 and BRCA2 mutations.  
Family ID Gene and mutation No. of No. of No. of No. of Age at Mean age Probability (%) of harboring a 
  brca ovca patients bilateral diagnosis of brca BRCA mutation according to: 
 cases     
in a 
family 
cases 
in a 
family 
with both 
brca and 
ovca 
brca 
cases 
in a 
family 
of the 
youngest 
brca 
patient 
diagnoses Shattuck-        Couch            Our 
  Eidens             et al.            study 
    et al.             (1997) 
   (1997) 
167 BRCA1, 3904C→A 2 4 1 0 39 45 99 83 100 
286 BRCA1, 4446C→T 15 3 1 3 25 46 100 83 100 
5004 BRCA1, 4446C→T 3 3 0 0 31 40 56 33 99 
425 BRCA1, 4446C→T 5 3 1 1 37 53 100 75 98 
112 BRCA1, 3604delA 1 3 1 0 41 41 98 89 97 
132 BRCA2, 9346(-2)A→G 6 2 0 0 35 51 75 16 90 
568 BRCA2, 5797G→T 1 2 0 0 37 37 88 44 88 
788 BRCA1, 3604delA 1 3 1 0 58 58 99 66 77 
6003 BRCA2, 999del5 5 1 0 1 27 42 52 33 77 
3 BRCA2, 8555T→G 3 1 1 2 27 46 81 83 77 
5137 BRCA1, 3604delA 2 1 0 0 29 32 25 55 72 
378 BRCA2, 7708C→T 5 1 1 1 30 38 95 92 68 
397 BRCA2, 999del5 4 1 0 1 33 39 69 44 58 
486 BRCA2, 7708C→T 7 1 0 0 34 51 45 16 56 
263 BRCA1, 5370C→T 3 2 1 0 50 55 94 66 55 
160 BRCA1, 2803delAA 2 2 0 0 51 62 20 7 50
5085 BRCA1, 3744delT 2 1 0 0 37 55 22 11 48 
55 BRCA2, 7708C→T 3 1 1 0 39 41 58 89 41 
274 BRCA1, 4216(-2)A→G 3 1 0 0 38 46 24 23 41 
158 BRCA2, 999del5 8 1 1 3 39 52 87 50 40 
1041 BRCA1, 1806C→T 1 2 0 0 57 57 10 11 30 
98 BRCA2, 9346(-2)A→G 3 1 0 0 42 52 20 16 30 
136 BRCA1, 4216(-2)A→G 3 0 0 2 28 35 21 12 27 
254 BRCA1, 1924delA 2 1 0 0 44 51 13 16 25 
130 BRCA2, 999del5 5 0 0 0 32 48 26 5 17
141 BRCA1, 5145del11 4 0 0 0 32 36 16 12 16 
280 BRCA1, 5382insC 2 1 0 0 49 56 9 11 15 
140 BRCA2, 8555T→G 5 0 0 1 36 49 20 5 11
157 BRCA2,
6495delGCA→C
3 0 0 0 49 51 3 3 2 
brca, breast cancer; ovca, ovarian cancer 
BRCA1 and BRCA2 mutation positive families were analyzed also separately. The results were very 
similar for both genes, the only difference being the number of breast cancer patients that was 
associated with a positive BRCA2 mutation status in the univariate analysis. In the multivariate 
analysis the same variables were significant for both genes, and therefore one model can be used for 
identifying both BRCA1 and BRCA2 carriers. Breast cancer patient diagnosed under the age of 40 
years was present in 11 (85%) and ovarian cancer in ten (77%) out of 13 BRCA2 positive families 
thus emphasizing the significance of these phenotypic characteristics also in families with a BRCA2
mutation. 
5.4 Inherited genetic defects in Li-Fraumeni syndrome (III) 
5.4.1. p53 
Among 44 families studied, four different disease-associated p53 mutations were identified in five 
families (5/44=11.4%; table 11). Two of the families were LFS, one LFL, and two phenotypically 
suggestive of LFS. The two families with the Arg248Gln mutation did not share a common 
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chromosome 17 haplotype, indicating independent mutational events. All mutations were located in 
the conserved region of the gene, and were either missense or nonsense substitutions. Another 
missense change in the coding region, Arg72Pro in exon 4, was found in 12 patiens. This alteration 
has previously been reported as a neutral polymorphism (Olivier et al., 2002), but recent data 
(Dunning et al., 1999; Langeröd et al., 2002; Martin et al., 2003) indicate that further analyses are 
needed to determine whether it has a role in breast cancer susceptibility or not. Several intronic 
variations were also observed, but these were located far from exon-intron boundaries and 
considered as polymorphisms with no functional significance.   
Table 11. Germline p53 and CHEK2 mutations and the clinical characteristics of the mutation carriers. 
Gene Mutation Amino acid 
change 
Exon Family 
ID
Index patient
a
 Family phenotype
a
p53 451C→A Pro151Thr 5 7154 Breast (29) LFS
b; Osteosarcoma (24), Leiomyosarcoma
     (29), Pancreatic adenoca (59),  
     Adrenocrtical adenoca (1) 
586C→T Arg196Stop 6 7106 Liposarcoma (32), 
Breast (35, 37) 
LFSb; Osteosarcoma (25), Breast (42e)
637C→T Arg213Stop 6 1084 Breast (28) PSL
d; Histiocytoma (64), Melanoma (67),  
     Lung (75) 
743G→A Arg248Gln 7 2204 Osteosarcoma 
(11), Breast (34) 
PSLd; Throat (65) 
743G→A Arg248Gln 7 7138 Breast (22) LFL
c; Brain (11), Liver (29), Bilateral  
     Breast (32), Leiomyosarcoma (54) 
CHEK2 1100delC Frameshift 10 7116 Breast (40) PSLd; Vaginal Melanoma (55), Endometrial 
     (46), Stomach (57e)Ovarian (30) 
 1100delC Frameshift 10 5130 Breast (34), 
Colorectal (34) 
PSLd; Breast (38), Meningioma (50),  
     Prostate (64e) Endometrial (52e) Kidney  
     (51e)
aCancer(s), age at diagnosis (years) in the brackets; bLi-Fraumeni syndrome; cLi-Fraumeni-like syndrome; 
dPhenotypically suggestive of Li-Fraumeni syndrome; e diagnosis could not be verified from the medical documents; the 
age at death 
5.4.2. CHEK2  
One apparently deleterious frameshift mutation in CHEK2, 1100delC, was found in two families 
(2/44=4.5%). Interestingly, the alteration is the same as identified in the report by Bell et al. (1999). 
The change was not observed among 95 healthy control individuals. The phenotype of the carrier 
families is only suggestive of LFS as there are no sarcomas or childhood cancers (table 11). In 
family 7116 the only patient whose sample was available was the proband diagnosed with breast 
cancer at age 40 years, and therefore the CHEK2-status of the sisters with vaginal melanoma and 
endometrial cancer, or of the mother with breast cancer, remains unknown. In another family with 
the 1100delC mutation, 5130, the index patient has been diagnosed with both breast and colorectal 
cancer at age 34 years, and has inherited the mutation from her mother with benign meningioma. 
Independently of this study, both the index patient and her mother were also found to carry a novel 
nonsense germline MSH6 mutation (2983G→T, Glu995STOP). A sister with breast cancer 
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diagnosed at 38 years does not have either of the mutations, and her tumor is therefore most likely 
sporadic. The chromosome 22 haplotype was not shared between families 7116 and 5130, but they 
may have a common allele at chromosome marker D22S275.  
Another observed alteration in the coding region was a missense substitution in exon three 
(470T→C, Ile157Thr). This was found in four families but also in two of 95 control individuals. 
The association of this variant with breast cancer risk is currently under investigation. Two intronic, 
probably neutral variants were also observed.  
5.4.3. CHEK1  
No mutations associated with the disease phenotype were identified in the CHEK1 gene. The 
Val47Ile (1411G→A) change in exon 13 was the only observed variant in the coding region. It was 
found in five patients and also in five of 95 healthy population controls. Three intronic 
polymorphisms located far from splice sites were also detected.  
5.5. CHEK2 1100delC mutation in breast cancer (IV) 
As the only pathogenic CHEK2 mutation observed at a time, 1100delC, was recurrently observed in 
breast cancer patients from different populations (Bell et al., 1999; study III), we wanted to further 
assess its role in breast cancer predisposition. We analyzed its frequency in 1035 unselected breast 
cancer patients and 507 familial breast cancer cases, and compared these to the frequency in 1885 
healthy control individuals. Observed mutation frequencies and calculated odds ratios compared to 
population controls are presented in table 12. 
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Table 12. Mutation frequency of the CHEK2 1100delC mutation among unselected breast cancer patients, 
breast cancer families, and healthy controls. 
Study cohort No. of 
Individuals
Mutation 
frequency 
(%)
OR
a
 95% CI
b
P value 
Population controls 1885 1.4    
Unselected breast cancer patients 1035 2.0 1.48 0.83-2.65 0.182 
   No family history 677 1.5 1.09 0.52-2.26  
   >1 affected first- or second-degree relative 358 3.1 2.27 1.11-4.63 0.021 
     Breast cancer only 318 3.5 2.56 1.25-5.23 0.008 
     Breast and ovarian cancer 40 0    
Breast cancer families 507 5.5 4.18 2.43-7.19 0.0002 
   According to cancer site:      
     Breast cancer only 448 5.1 3.87 2.19-6.85 <0.00005
     Breast and ovarian cancer 59 6.8 5.20 1.75-15.41 0.012 
   According to number of affected relatives:      
     Index with 1 affected first-degree relative 291 6.2 4.70 2.55-8.71 <0.00005
     Index with >2 affected relatives 216 4.6 3.50 1.65-7.30 0.002 
       Index with affected first-degree relatives   164 4.3 3.19 1.36-7.46 0.013 
       Index with affected second-degree relatives only 52 5.8 4.38 1.28-14.95 0.041 
aOR, odds ratios, compared with population controls;  bCI, confidence interval 
The frequency of the 1100delC mutation among population controls was 1.4% (26/1885). Among 
the 1035 breast cancer patients unselected for family history or age at diagnosis, a slightly higher 
frequency (2.0%, 21/1035) was seen (OR 1.48, 95% CI 0.83-2.65). Of all unselected patients, 358 
(34,6%) had reported a positive family history of at least one affected first- or second-degree 
relative, and 11 of these carried the 1100delC variant (3,1%, OR 2.27, 95% CI 1.11-4.63). 
Interestingly, an association of the 1100delC with bilateral breast cancer was detected. Of the 1035 
unselected breast cancer patients the information on laterality was available on 627 cases. Of these, 
33 had bilateral disease, 4 of which were found to carry the 1100delC mutation (4/33=12.1%). The 
frequency was markedly higher compared to 12 of 594 (2.0%) patients with unilateral cancer, with 
an OR of 6.17 (95% CI 1.87-20.32, P=0.007). Two of the carriers had no family history of breast 
cancer and two had one affected first degree relative. Notably, none of the 40 patients with relatives 
affected with ovarian cancer carried the 1100delC mutation. 
To estimate the role of CHEK2 1100delC mutation in familial breast cancer, we further analyzed 
507 breast cancer patients who had affected breast and/or ovarian cancer relatives and who were not 
found to carry deleterious BRCA1 or BRCA2 mutations. A significantly higher frequency of 
1100delC was found among these as compared to population controls (28/507, 5.5%, OR 4.18, 95 
% CI 2.43-7.19). The frequency of 1100delC was high among patients with only one affected first 
degree relative (18/291, 6.2%, OR 4.70, 95% CI 2.55-8.71 as compared to population controls) as 
well as in patients with a strong family history (10/216, 4.6%, OR 3.50, 95% CI 1.65-7.30). The 
segregation of the mutation with the disease phenotype was tested in five families where enough 
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samples were available. Incomplete segregation was observed, as both unaffected carriers and 
cancer patients with no mutations were observed. For example, in one family the mutation was 
observed in all breast cancer patients (diagnosed at 36, 36, 67, and 68 years) but also in four 
unaffected females (aged 41, 49, 63, and 75 years). In another family the only carriers were a breast 
cancer patient diagnosed at 63 years and her healthy 70 years old sister. Another affected sister 
(breast cancer diagnosis at 66 years) and cousin (breast cancer diagnosis at 57 years) were mutation 
negative.  
The mean age of breast cancer diagnosis among all 1100delC carriers tended to be slightly younger 
than among non-carriers, with 52.7 years vs. 54.8 years (P=0.062). Incomplete segregation, 
relatively high frequency in healthy population, and clustering in families with only a few affected 
family members suggest that CHEK2 1100delC acts as a low-penetrance susceptibility allele in 
breast cancer.  
Expression of the CHEK2 protein was explored using tissue microarray with 124 tumor samples 
from BRCA1 and BRCA2 mutation negative families. Reduced expression was observed in 21 out of 
124 tumors (16.9%). All four tumor samples from patients with a 1100delC mutation exhibited 
reduced expression while none of the 103 patients with normal CHEK2 staining carried the 
mutation (P<0.0005). Three of the four tumors from patients with 1100delC mutation showed 
highly reduced immunostaining, suggesting that also the other allele may have been lost. As the 
epitope of the DCS-270 antibody is located within the N-terminus of the protein, far before 
1100delC, these results suggest that besides disrupting the kinase activity of the protein, the 
1100delC mutation may also affect the expression and/or stability of the CHEK2 mRNA or protein 
product. 
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6. DISCUSSION 
6.1. Contribution of BRCA1 and BRCA2 to breast cancer in Finland   
(I, II) 
The contribution of germline BRCA1 and BRCA2 mutations to breast cancer burden differs in 
various populations (Szabo & King, 1997). Both the population based study of unselected breast 
cancer patients (I) and the analysis of breast cancer families (II) indicate a low frequency of such 
mutations in Finland. Altogether 19 mutation positive patients were identified among 1035 (1.8%) 
breast cancer patients unselected for family history and age at diagnosis (I). This is much lower than 
the reported prevalence of BRCA1 and BRCA2 founder mutations in unselected Icelandic (7.7-
10.4%) (Johannesdottir et al., 1996; Thorlacius et al., 1997, 1998) and Ashkenazi (6.7-11.7%) 
(Fodor et al., 1998; Warner et al., 1999) breast cancer patients. Also studies of BRCA1 whole-gene 
mutation screening have revealed somewhat higher frequencies, such as 3.3% in patients of 
European origin from North Carolina, USA (Newman et al., 1998), and 3.8% among Chinese 
patients in Hong Kong (Tang et al., 1999). A lower frequency of 0.8% was obtained in 1000 
unselected Japanese patients, but here only exon 11 of BRCA1 was analyzed (Emi et al., 1998). A 
similar frequency as seen in Finnish patients was obtained in a large, retrospective analysis of early-
onset British breast cancer cases (diagnosis below 36 years) (Peto et al., 1999). There, a combined 
mutation frequency of 2.8% was estimated for BRCA1 and BRCA2. This figure was based on 
correction for assuming a 63% mutation detection sensitivity, as well as extrapolation of findings 
from early-onset breast cancer to the total breast cancer population presuming high penetrance for 
the mutations.  
Simultaneously or right following our study a number of reports were published where the BRCA
mutations were analyzed in breast cancer patients unselected for family history (table 13). In most 
of the studies, however, the focus has been on early-onset disease, only BRCA1 has been analyzed, 
or the study cohort has comprised only of dozens or a few hundred cases. When summarizing data 
from such reports, the combined prevalence of both BRCA1 and BRCA2 germline mutations among 
young breast cancer patients unselected for family history has been around 5-10%. Among studies 
where patients have been unselected both for family history and age at diagnosis, excluding the 
studies of Icelandic and Ashkenazis, the mutation frequencies have varied between 3.1% in Canada 
and 6.7% in Pakistan (van der Looij et al., 2000; Chappuis et al., 2001; De Leon Matsuda et al., 
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2002; Liede et al., 2002). The 1.8% frequency observed in our study (I) is lower compared to results 
obtained in other populations. This highlights the differences between BRCA1 and BRCA2 mutation 
frequencies in various populations, and refers that population-specific studies may be required in 
order to obtain reliable prevalence estimations in each particular population. The low frequency also 
indicates a moderate contribution of germline BRCA1 and BRCA2 mutations to breast cancer 
incidence in Finland. 
Table 13. Germline BRCA1 and BRCA2 mutations among breast cancer patients unselected for family 
history. 
Reference Population No. of Ages Type of Mutation frequency
patients studied mutation
screening
BRCA1
(%)
BRCA2
(%)
BRCA1/2
(%)
Europe
   Johannesdottir et al. (1996) Icelandic 459 All ages F - 8.5 -
   Thorlacius et al. (1997) Icelandic 632 All ages F - 7.7 -
   Garcia-Patino et al (1998) Spanish 105 All ages W 5.7 - -
   Peto et al. (1999) British 254 <35 W 3.5 2.4 5.9
   Peto et al. (1999) British 363 36-45 W 1.9 2.2 4.1
   Ellis et al. (2000) British 110 <35 W 3.6 - -
   ABCSG (2000) British 1220 <55 W 0.7 1.3 2.0
   van der Looij et al. (2000) Hungarian 500 All ages F 3.4 0.2 3.6
   Papelard et al. (2000) Dutch 642 All ages P 1.6 - -
   Yazici et al. (2000) Turkish 52 <50 P 3.8 1.9 5.8
   Loman et al. (2001) Swedish 234 <40 W 6.8 2.1 9.0
North America
   FitzGerald et al. (1996) US (MA) 30 <30 W 13 - -
   Krainer et al. (1997) US (MA) 73 <32 W - 2.7 -
   Langston et al. (1996) US (WA) 80 <35 W 7.5 - -
   Malone et al. (1998) US (WA) 193 <35 W 6.2 - -
   Malone et al. (2000) US (WA) 203 <35 W 5.9 3.4 9.4
   Newman et al. (1998) US (NC) 211 All ages W 1.4 - -
   Anton-Culver et al. (2000) US (CA) 673 All ages F 1.6 - -
   Tonin et al. (2001) French Canadian 61 <40 F 6.6 6.6 13.1
   Chappuis et al. (2001) French Canadian 127 All ages F 0 3.1 3.1
Australia
   Southey et al. (1999) Australian 91 <40 W 3.3 - -
   Hopper et al. (1999) Australian 388 <40 P 2.3 2.3 4.6
Asia
   Emi et al. (1998) Japanese 1000 All ages P 0.8 - -
   Tang et al. (1999) Chinese (Hong Kong) 130 All ages W 3.8 - -
   Sng et al. (2000) Chinese (Singapore) 70 <40 W 8.6 - -
   Ho et al. (2000) mixed (Singapore) 43 <35 W 7.0 - -
   De Leon Matsuda et al. (2002) Philippine 294 <65 P 1.0 4.1 5.1
   Yassaee et al. (2002) Iranian 83 <45 P 3.6 2.4 6.0
   Liede et al. (2002) Pakistani 341 All ages P 4.4 2.3 6.7
Ashkenazi Jewish
   Fodor et al. (1998) 412 All ages F 8.3 3.6 11.7
   Warner et al. (1999) 268 All ages F 3.7 3.0 6.7
ABCSG, Anglian Breast Cancer Study Group; W, whole coding region; P, partial coding region; F, founder mutations; MA,
Massachusetts; WA, Washington; NC, North Carolina; CA, California
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The 1.8% frequency reported in study I obviously represents an underestimate as only the 19 
mutations identified at the time in the Finnish population were studied. However, we believe that 
the result is well representative of the BRCA1 and BRCA2 mutation burden in Finland, as recurrent 
founder mutations were found to account for 84% of the Finnish BRCA1 and BRCA2 families when 
the whole coding regions of the genes were screened (Vehmanen et al., 1997a, b; Huusko et al., 
1998). The importance of BRCA founder mutations was further emphasized in study II where the 
vast majority (24/29) of mutations were recurrent, and in a study of unselected ovarian cancer 
patients where all but one BRCA mutations (92%) were founder mutations (Sarantaus et al., 2001b). 
Furthermore, additional families have been shown to be carriers of the previously recognized 
founder mutations, and although some novel mutations have also been identified, this data supports 
the major role of the recurrent founder mutations in Finland (unpublished data). So far, large 
genetic rearrangements that have been found in several populations (e.g. Petrij-Bosch et al., 1997; 
Puget et al., 1997; Swensen et al., 1997; Nordling et al., 1998; the BRCA1 exon 13 duplication 
screening group, 2000; Unger et al., 2000; Wang et al., 2001a; Hofmann et al., 2002), and that 
constitute the majority of BRCA1 mutations in the Netherlands and Northern Italy (Petrij-Bosch et 
al., 1997; Montagna et al., 2003), have not been observed in Finnish breast and/or ovarian cancer 
families (Lahti-Domenici et al., 2001; Sarantaus et al., 2001b). Linkage analysis has also suggested 
possible linkage to either BRCA1 or BRCA2 in only four of 24 additional large breast-ovarian 
cancer families (Kainu T, unpublished observations). The screening of the known mutations 
provides therefore a unique and rapid way to analyze the impact of BRCA1 and BRCA2 mutations in 
Finland without a bias towards any individual founder mutation.
In the study of 148 breast and breast-ovarian cancer families a total of 29 BRCA mutations were 
identified (19.6%; study II). Most mutations (24/29) were found in families with both breast and 
ovarian cancer, and altogether 50% of such families carried a mutation. In a subgroup of breast-
ovarian cancer families with also a young breast cancer patient (diagnosis below 40 years) the 
mutation frequency was 80% compared to 29% among families without such a patient. In site-
specific breast cancer families the mutation frequency was only 5%. Even lower frequency of 1.5% 
was obtained among families with no early-onset cases compared to 12.5% in families with such a 
patient. Mutations were absent altogether among 21 families with 4 or more cases of breast but no 
ovarian cancer or young breast cancer patient (II). This is in agreement with study I where all 15 
patients with strong breast cancer family history were also mutation negative. While mutation 
frequencies among breast-ovarian cancer families, especially those with early-onset breast cancer, 
are very high, the frequencies among site-specific breast cancer families obtained here and in 
previous studies of Finnish breast and breast-ovarian cancer families (Vehmanen et al. 1997a,b; 
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Huusko et al. 1998) are lower than those seen in most other populations (Szabo & King, 1997). 
Although the comparison of the frequencies is not straightforward as families have been ascertained 
using different definitions and screening methods have been variable, these data indicate a smaller 
contribution of BRCA1 and BRCA2 to familial breast cancer in Finland compared to most other 
populations. In many populations, germline BRCA1 and BRCA2 mutations are thought to account 
for 15-20% of familial breast cancer and nearly all of the large families with both early-onset breast 
cancer and ovarian cancer (Ford et al., 1998; Nathanson & Weber, 2001). In line with study II, 
much lower frequencies have been observed among families with fewer affected family members 
and only site-specific, late-onset breast cancer (Rebbeck et al., 1996; Schubert et al., 1997; Serova 
et al., 1997; Vehmanen et al., 1997a; Ford et al., 1998). Although some mutations may have been 
missed and some families may represent aggregations of sporadic cases, these results suggest that 
other genes may account for a substantial fraction of familial aggregation of breast cancer.  
6.2. Identification of probable BRCA1 and BRCA2 mutation carrier 
families (I, II) 
Genetic screening would be of greatest benefit in families with both a high cancer risk, i.e. multiple 
affected family members (Fodor et al., 1998), and a high probability of carrying a predisposing 
mutation. In order to better identify such families we chose to analyze families with three or more 
breast and/or ovarian cancer cases, the family type most often seeking genetic counseling. The 
ultimate aim was to devise a probability model that could be used for estimating the likelihood of 
carrying a deleterious BRCA1 or BRCA2 mutation in each family (II). 
Numerous variables were tested for the possible association with a positive mutation status, and 
many statistically significant associations were observed in univariate analysis. In multivariate 
analysis, however, only two variables were found as independent predictors of a mutation. These 
were the number of ovarian cancer cases in a family and the age at diagnosis of the youngest breast 
cancer patient (II). Previously, the presence of breast and ovarian cancer in the same patient has 
been correlated with a positive mutation status (Couch et al., 1997; Shattuck-Eidens et al., 1997), 
but here it was not significant in multivariate analysis. This is probably because it is not an 
independent factor but closely associated with ovarian cancer cases overall. Also bilateral breast 
cancer has been associated with BRCA mutations (Shattuck-Eidens et al., 1997; Frank et al., 1998; 
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Ligtenberg et al., 1999), but in our study it didn’t reach statistical significance in univariate 
analysis, and was therefore excluded from further analysis.  
According to American Society of Clinical Oncology (1996) the probability of finding a deleterious 
mutation should exceed 10% in order to justify the mutation screening. Here, 63 of the 148 study 
families (43%) obtained a probability greater than this arbitrary cut-off value, including 28/29 of the 
positive cases. Thus, nearly half of the families that exceeded the cut-off limit were mutation 
carriers. The mean probabilities for mutation positive and negative families were 55% and 11%, 
respectively. Accordingly, this model may be used in directing the mutation screening to a 
considerably smaller proportion of families, without losing specificity. 
When BRCA1 and BRCA2 carriers were analyzed both together and separately, it became evident 
that one common model can best distinguish all mutation carriers. This emphasizes that besides 
BRCA1, also BRCA2 confers a high risk for ovarian cancer and early-onset breast cancer. The 
similarity between BRCA1- and BRCA2-carriers was further confirmed when our data set was tested 
in two models originally designed for detecting only BRCA1 carriers (Couch et al., 1997; Shattuck-
Eidens et al., 1997). Using the 10% cut-off level the proportion of identified mutation carrier 
families was 93% in Shattuck-Eidens’ model (1 BRCA1 and 1 BRCA2 mutations missed), 86% in 
Couch’s model (1 BRCA1 and 3 BRCA2 mutations missed) and 97% in our model (1 BRCA2
mutation missed). The proportion of found mutations is higher in the model developed in our study 
since it has been designed particularly for this study cohort, and the determination of sensitivity as 
well as specificity of this model requires analysis of a separate test population. The one mutation 
positive family missed in all three models has three affected breast cancer patients all diagnosed at 
later age. This indicates that all mutation carrier families cannot be found by any practical criteria, 
without increasing the number of families to be studied considerably.  
The probability model devised in study II was designed to assess the carrier probabilities in families 
with three or more affected cases and is not applicable to cases with less profound family history. 
However, the same features were found to associate with a positive mutation status when analyzing 
the phenotypes of the BRCA1 and BRCA2 mutation carriers found among unselected breast cancer 
patients (I). Nearly 70% of the mutation positive cases were characterized by either ovarian cancer 
family history or an early-onset breast cancer, or both. The BRCA mutation frequency among the 
index cases diagnosed before 40 years was eight times higher as compared to those diagnosed at 40 
years or older (9.9% vs. 1.2%, P<0.0005).  The other predictor of a mutation, ovarian cancer case in 
a family, was even more significant, as less than 4% of all unselected breast cancer patients reported 
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a family history of ovarian cancer but almost half (42%) of mutations were found in this small 
group (I). This corresponds to 34 times higher mutation frequency as compared to patients with no 
family history of either breast or ovarian cancer. Therefore, the presence of a young breast cancer 
patient (diagnosis below 40 years) or an ovarian cancer case in a family can be considered as 
indicators of a possible BRCA mutation. This robust definition would have identified 97% of 
mutation positive breast cancer families (II) and 68% of mutation positive patients among 
unselected breast cancer cases (I). 
Only one mutation was observed among 295 patients with one first-degree relative affected with 
breast or ovarian cancer (0.3%)(II). This suggests that mutation screening of BRCA1 and BRCA2 in 
families with only two affected first-degree relatives is not feasible in Finland. This is in contrast 
with the results from Goelen et al. (1999), who found that 24% of Belgian families with two first-
degree relatives, of whom the other had ovarian cancer or the age of breast cancer onset below 50 
years, carried a mutation. Altogether 39 families in our study had either ovarian cancer case or a 
young breast cancer patient (diagnosis below 40 years), but the mutation frequency among these 
was one tenth of that observed in Belgium, only 2.6%. The low proportion of mutations in this 
study population might partly be explained by the accumulation of sporadic cases. It could also 
derive from population-specific differences in BRCA1 and BRCA2 frequencies. There may also be 
some population-specific genetic or environmental factors that modify the phenotype of the BRCA1
and BRCA2 carrier families. Thus as the most likely predictors of a positive mutation status are the 
same in different populations, it may be necessary to define specific probability models and criteria 
for each population specifically.  
Screening of both BRCA1 and BRCA2 genes is very laborious and expensive, and genetic testing 
may be extremely stressful for the families. It is therefore important to identify phenotypic clues 
that would predict the likelihood of finding BRCA1 and BRCA2 mutations. The question as to how 
to find the most BRCA1 and BRCA2 mutations by screening the least number of specimens can 
according to our results best be accomplished by identifying families with at least three affected 
relatives, of whom at least one should be diagnosed with an ovarian cancer or early-onset breast 
cancer. The probability model developed in study II should be a useful tool in genetic counseling 
and focusing the mutation analyses, and thereby increasing the cost-effectiveness of the genetic 
screening. At present, the model is being tested in clinical practice at the Department of Clinical 
Genetics, HUCH, and preliminary results have shown it to perform quite efficiently (K. Aittomäki, 
personal communication). However, despite the advantages of probability models in genetic 
counseling, it is important to bear in mind that risk assessment is only an estimate. Optimal 
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counseling requires an experienced clinical geneticist, and clinical judgment remains a key 
component in estimating prior probabilities and the possible need of genetic testing (Domchek et 
al., 2003). This is particularly important in families with rare features such as male breast cancer, 
pancreatic cancer, or an individual with multiple primary cancers, that may imply of a possible 
germline BRCA mutation. The low frequency of BRCA mutations among unselected breast cancer 
patients and patients with only a modest family history suggest that the mutation screening is not 
warranted in the general breast cancer population (I, II), and substantiate the strict criteria 
previously suggested for BRCA1 testing (Couch et al., 1997; Shattuck-Eidens et al., 1997; Newman 
et al., 1998). 
6.3 Predisposing genes in Li-Fraumeni syndrome (III) 
Five of the 44 study families with either LFS, LFL, or phenotypical features of LFS were found to 
carry deleterious germline p53 mutations. The most common p53 mutation found to date in LFS, 
Arg248Gln, was detected here in two families. In another family the proband was most probably 
carrying a de novo mutation, since her parents had deceased cancer-free at ages 71 and 81 years, 
and also her six siblings were free of cancer. The proband herself has been diagnosed with two 
primary tumors that are highly indicative of LFS, i.e. osteosarcoma at 11 years and breast 
carcinoma at 34 years. The two families with the Arg248Gln mutation were found to carry distinct 
chromosome 17 haplotypes, a finding that supports this site as a mutational hot spot. Arginine 248 
is a key residue involved in direct contact between p53 and DNA (Cho et al., 1994), and mutations 
at this residue therefore perturb interactions between p53 and its target sequences. Also two other 
alterations found in this study, Arg196STOP and Arg312STOP, have previously been reported as 
pathogenic mutations (Olivier et al., 2002). In contrast, there are no reports on germline Pro151Thr 
change, but several features indicate that this is a deleterious mutation: (i) inherited disease-
associated mutations in the same codon imply that this site is important for the protein function, (ii) 
somatic Pro151Thr has been found in several tumor types, (iii) all five cancer patients in the family 
carried the mutation but it was absent in 95 healthy controls, and (iv) wild-type allele was lost in a 
leiomyosarcoma tumor sample.    
The association of another coding variant, Arg72Pro, with cancer susceptibility is still uncertain. 
Here it was observed in 12 patients. The variant is rather common in the general population 
(Beckman et al., 1994; Själander et al., 1995), and has previously been considered as a neutral 
polymorphism in Li-Fraumeni syndrome (Olivier et al., 2002). However, recent data imply that it 
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may in fact influence the cancer risk. An increased risk of cervical cancer has been associated with 
the Arg72 allele (Storey et al., 1998; Zehbe et al., 1999; Andersson et al., 2001), although the 
finding has been challenged by others (Helland et al., 1998; Hildesheim et al., 1998; Josefsson et 
al., 1998; Rosenthal et al., 1998). The Pro72 variant, on the other hand, is suggested to associate 
with the early onset of the squamous cell carcinomas of the head and neck (Shen et al., 2002) as 
well as lung carcinomas in smokers (Fan et al., 2000). There is also a correlation between the 
frequency of the allele encoding Pro72 and latitude, suggesting that this allele might be selected for 
its protective effect against high levels of ultraviolet light and thus, skin cancer (Beckman et al., 
1994). Functional analyses have revealed differences in biochemical properties between the two 
allelic variants. The Arg72 form is shown to induce apoptosis markedly better (Dumont et al., 
2003), to suppress cellular transformation more efficiently (Thomas et al., 1999), and to be 
significantly more susceptible to degradation induced by Human Papillomavirus E6 protein (Storey 
et al., 1998) than the Pro72 variant. It also enhances the ability of certain p53 mutants to form stable 
complexes with p73 protein (Marin et al., 2000). In breast cancer, an increased risk has been 
observed for both Arg/Pro heterozygotes and Pro homozygotes (Själander et al., 1996), but the 
effect was not seen in two other studies (Kawajiri et al. 1993; Wang-Gohrke et al., 1998). In a joint 
analysis combining data from Kawajiri et al. (1993), Själander et al. (1996), and Wang-Gohrke et 
al. (1998) a modest, statistically significant correlation between the Arg/Pro genotype and breast 
cancer was seen (OR 1.23, 95%CI  1.02-1.58) (Dunning et al., 1999). To make things more 
complicated, a six-fold higher frequency of the homozygous Arg72 genotype was observed among 
BRCA1/2 carriers with multiple primary cancers compared to patients with only one cancer, while 
the Pro72 allele was associated with an earlier age of breast cancer diagnosis among women with a 
BRCA1 mutation (Martin et al., 2003). Higher occurrence of somatic p53 mutations have also been 
observed in breast carcinomas with the Arg72 allele, a difference that was not seen in colorectal 
carcinomas (Langeröd et al., 2002). The association of both Arg72 and Pro72 alleles with several 
cancer types suggests that they may modulate the response to pathogens and other environmental 
carcinogens in a tissue-specific manner. Conflicting results on cancer susceptibility warrants further 
studies with larger sample sizes and specific attention on controls and confounding factors.  
No germline p53 mutations were observed in 17 families that also fulfill the criteria for hereditary 
breast cancer (three or more cases in first- or second-degree relatives). This is in line with previous 
studies where inherited p53 defects have very rarely been seen in familial, early-onset, or bilateral 
breast cancer, or in patients unselected for family history or age at diagnosis (Prosser et al., 1991; 
Börresen et al., 1992; Lidereau & Soussi, 1992; Sidransky et al., 1992; Warren et al., 1992; Zelada-
Hedman et al., 1997; Rapakko et al., 2001; Martin et al., 2003). Somatic p53 mutations are, 
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however, more frequent and show a distinctive spectrum in breast tumors from BRCA1 and BRCA2
carriers compared to tumors with no such mutations (Crook et al., 1998; Gretarsdottir et al., 1998; 
Phillips et al., 1999; Greenblatt et al., 2001). p53 has also been suggested to have a crucial role in 
BRCA1 and BRCA2 associated tumorigenesis (Xu et al., 1999a, 2001; Jonkers et al., 2001), and the 
Arg72 allele has been proposed to modify the BRCA1 associated breast cancer risk (Martin et al., 
2003). p53 plays thus a major role in hereditary breast cancer, even though germline mutations are 
almost exclusively seen in the context of LFS. 
CHEK1 has an important role in p53-mediated response to DNA damage (Shieh et al., 2000; 
Gottifredi et al., 2001). Somatic mutations have also been identified in several different cancer 
types (Bertoni et al., 1999; Haruki et al., 2000; Menoyo et al., 2001), and mice heterozygous for 
Chek1 mutations develop tumors at accelerated rate (Liu et al., 2000). Despite being a plausible 
candidate for LFS and breast cancer predisposition, no mutations were detected in our analysis. 
Mutations were absent also in a study by Bell et al. (1999), where four LFS and 18 LFL-families 
were analyzed. Therefore, it seems unlikely that CHEK1 is a major gene for LFS or for hereditary 
breast cancer predisposition. 
Altogether two out of three LFS families, one of seven LFL families, and two out of 34 families 
featuring only phenotypical characteristics of LFS were found to harbor a deleterious p53 mutation. 
This is in concordance with the previous studies where p53 mutations have been detected in about 
70% of LFS and 25% of LFL families (Eng et al., 1997; Varley et al., 1997b). It also confirms that 
the strict criteria defined by Li et al. (1988) and Birch et al. (1994) are accurate and applicable when 
considering genetic screening. Genetic counseling of families with such a devastating disease 
requires an experienced clinical geneticist, and clinical management remains complicated even after 
positive test result. Given the diversity and unpredictability of tumors in LFS, no widely accepted 
screening procedure has been devised. Therefore, it will be important to establish reliable estimates 
of penetrance and age-specific risks for the various component cancers of the syndrome, as well as 
to determine the different risks associated with distinct mutations. The possibility of inducing 
tumors that would otherwise not have occurred should also be recognized, as radiation induced 
tumors have been observed in LFS patients (Bech-Hansen et al., 1981, Hisada et al., 1998). This 
applies particularly for mammography screening of breast cancer and radiotherapy as a cancer 
treatment. Genetic testing of children remains also problematic; thus far it is widely accepted that 
children are not tested routinely, and each case is treated on its own merits. Yet another difficult 
question is neonatal testing; what implications would such screening have on both parents and a 
baby. Furthermore, as germline p53 mutations explain only a proportion of LFS and LFL families, 
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the absence of a mutation does not allow complete reassurance, and a risk of a predisposing 
mutation in another gene remains high. As CHEK1 and CHEK2 (see section 6.4) are unlikely the 
genes behind the remaining LFS and LFL families, there are probably other, as yet unidentified 
gene(s) that may explain the etiology of the syndrome. 
6.4. CHEK2 in cancer predisposition (III, IV) 
Two families among the 44 LFS, LFL, or families with phenotypical features of LFS carried the 
CHEK2 1100delC mutation. This mutation is most likely pathogenic, as it disrupts the kinase 
activity of the protein (Wu et al., 2001, Lee et al., 2001). The variant was not seen among 95 
healthy control individuals. Interestingly, the same mutation was reported in the study by Bell et al. 
(1999). In contrast to Bell and co-workers (1999), who found their mutation in a classical LFS 
family, the phenotypes of the mutation carrier families in this study were not typical for LFS as the 
hallmark cancers of the syndrome, sarcomas and childhood malignancies, were lacking. Instead, in 
both families, the mutation was found in a breast cancer patient who also had a first-degree relative 
affected with breast cancer. In the other CHEK2 1100delC positive family an additional germline 
MSH6 mutation was identified independently of this study. Both the CHEK2 and MSH6 mutations 
were found in the index patient diagnosed with breast and colorectal cancer and in her mother with 
benign meningioma. As the CHEK2 is now shown to act as a low-penetrance breast cancer allele 
(see below) and MSH6 is known to predispose to colorectal cancer, it may be that the index 
patient’s breast carcinoma is due to the CHEK2 mutation and colorectal tumor due to the MSH6
mutation, although the additive or co-operative effect of the mutations cannot be ruled out. The 
sister of the index patient has been diagnosed with breast cancer at the age of 38 years but she was 
found not to carry either of the mutations and her tumor is therefore most likely sporadic. 
The observation that the only seemingly pathogenic mutation in CHEK2 found in LFS/LFL-
families at the time, 1100delC, was identified in breast cancer patients in two different populations, 
and the central role of CHEK2 protein in regulating p53 and BRCA1, two genes known to be 
important in breast cancer development, prompted us to evaluate the role of 1100delC in breast 
cancer susceptibility in general. First we analyzed the frequency of the 1100delC mutation in a 
consecutive series of 1035 unselected breast cancer patients, and compared it to the frequency 
among 1885 healthy control individuals. The variant was observed in 21 patients (2.0%), a slightly 
higher frequency than in population controls, but the difference did not reach statistical significance 
(OR 1.48, 95% CI 0.83-2.65). However, 11 of the 318 patients with at least one close relative 
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affected with breast cancer carried the mutation (3.5%, OR 2.56, 95% CI 1.25-5.23 as compared to 
population controls). Interestingly, the 1100delC mutation was found to have a significant 
association with bilateral breast cancer as 4/33 patients with bilateral disease compared to 12/594 
with unilateral cancer were found to carry a mutation (OR 6.17, 95% CI 1.87-20.32). This is in 
concordance with our previous observation of an increased risk for contralateral breast cancer in 
BRCA1/2-negative breast cancer families (Eerola et al., 2001a), and further studies to fully 
comprehend the role of CHEK2 in bilateral breast cancer are underway.   
The same cohort of unselected breast cancer patients was analyzed for BRCA1 and BRCA2
mutations in study I. There, 19 cases (1.8%) were found to carry a mutation. Most BRCA mutations 
(11 of the 19 mutations, 58%) were found in patients with a strong family history, while in contrast 
only three (3/21, 14%) CHEK2 mutations were found in this group. The mean age at breast cancer 
diagnosis among CHEK2 1100delC carriers was only marginally younger than among non-carriers 
(54.7 years vs. 57.4 years), whereas the difference between BRCA mutation carriers and non-
carriers was eight years (49.7 years vs. 57.5 years). Another phenotypical feature that may differ 
between the CHEK2 1100delC carrier families and those with BRCA mutations is that no 
association of the 1100delC mutation with ovarian cancer was observed. None of the 40 patients 
who had a relative with ovarian cancer carried the CHEK2 1100delC mutation, whereas eight were 
BRCA positive (20%). All CHEK2 1100delC mutations were found in patients who tested negative 
for BRCA-mutations. These data suggest that the CHEK2 1100delC mutation is a low-penetrance 
predisposition allele for breast cancer that confers distinct phenotypic consequences compared to 
BRCA mutations.    
To further assess the contribution of CHEK2 1100delC mutation to familial breast cancer, we 
studied its frequency in 507 breast and breast-ovarian cancer families with no BRCA1 or BRCA2
mutations, and compared it to the frequency among 1885 healthy control individuals. The mutation 
was found at a significantly higher frequency in breast cancer families (5.6%) than in population 
controls (1.4%, OR 4.18, 95% CI 2.43-7.19). The effect was seen both in patients with a strong 
family history (4.6%, OR 3.5, 95% CI 1.65-7.3) and among patients with only one affected first- 
degree relative (6.2%, OR 4.7, 95% CI 2.55-8-71). Segregation analysis revealed that the mutation 
segregates incompletely with the disease phenotype, as both unaffected female carriers and non-
carrier breast cancer patients were identified. An observation that the frequency of the CHEK2
1100delC variant is significantly higher among affected individuals from non-BRCA1/2 families 
than in healthy population controls indicates that it confers an increased risk for breast cancer. The 
incomplete segregation, rather high frequency in healthy controls, and clustering in families with 
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only a few affected family members suggest, however, that the risk is only modestly increased, and 
support the hypothesis that the variant acts as a low-penetrance predisposition allele. High 
frequency of CHEK2 1100delC mutation in families with only a few affected relatives, the most 
common type of breast cancer families, suggests that this genetic alteration is still likely to make a 
significant contribution to familial clustering of breast cancer at a population level. Previously, 
several polymorphisms in many different genes have been observed at higher frequency among 
breast cancer patients than in healthy controls (Dunning et al. 1999), but none of these have been 
found to associate with the familial disease. CHEK2 1100delC may therefore be the first example of 
a low-penetrance allele that has a significant contribution to familial clustering of breast cancer.
This data fits well also to a recently proposed model of breast cancer susceptibility where 
individually small effects of many genes may act multiplicatively and thereby form a polygenic 
basis for cancer risk (Antoniou et al., 2001, 2002). The low penetrance of the mutation may reflect 
the role of CHEK2 as a modifier of checkpoint response, or it may be explained by the partly 
compensatory roles of CHEK2, p53, and possibly CHEK1 and some other proteins, as some of 
these protein(s) may partly compensate the loss of functional CHEK2 (Bartek & Lukas, 2003).  
Immunohistochemical analysis showed reduced CHEK2 expression in 21 out of 124 breast tumors 
analyzed (16.9%). All four tumors from CHEK2 1100delC carriers from different families exhibited 
reduced expression, when in contrast none of the 103 patients with normal staining pattern were 
found to carry a mutation (P<0.0005). This suggests that the 1100delC mutation reduces the amount 
of functional CHEK2 protein in the cell. Furthermore, three of the four tumors were among samples 
that showed most extremely defective CHEK2 staining, indicating that also the second allele may 
have been lost. As the epitope of the DCS-270 antibody is far more N-terminal than the 1100delC 
and should therefore been preserved even in 1100delC poplypeptides, the mutation may, besides 
disrupting the kinase activity, influence the expression and/or stability of the CHEK2 mRNA or 
protein product. Although further studies with larger sample material are needed, the fact that all 
available tumors from 1100delC carriers showed clearly aberrant immunostaining suggests that 
immunohistochemical analysis may be used as a preliminary CHEK2 1100delC screening method. 
Simultaneously with our study, similar results were reported by Meijers-Heijboer et al. (2002). Both 
studies thus independently confirm the observation of CHEK2 1100delC as a low-penetrance breast 
cancer predisposition allele. In the study by Meijers-Heijboer and coworkers (2002), the prevalence 
of the CHEK2 1100delC mutation among families with no BRCA1/2 mutations was 4.2% compared 
to 1.1% among healthy controls. The variant was estimated to confer a two-fold increase in breast 
cancer risk, and an association with increased male breast cancer risk was also observed. 
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Interestingly, all carriers were shown to share the same allele in a polymorphic marker D22S275 
(Meijers-Heijboer et al., 2002). The samples in our breast cancer study cohorts have thus far not 
been genotyped for this marker, but the two 1100delC families in study III possibly share the 
common D22S275 allele. The families do not, however, segregate common chromosome 22 
haplotypes, suggesting that either the mutation has a very ancient common ancestor or that the site 
is a mutational hot spot. Further collaborative studies with additional markers are needed to unravel 
this question.  
The other CHEK2 variant seen in our study, Ile157Thr, was found in four families. It was also 
present in two of 95 control individuals. Like 1100delC, this variant too was found in the report by 
Bell et al. (1999). The role of this alteration in breast cancer predisposition is, however, more 
contentious. In the original report by Bell et al. (1999) it was found in a patient with three primary 
tumors (breast and lung carcinomas and melanoma) but not among 50 control individuals. In a 
subsequent report by the same group the variant was seen in a breast cancer patient with classical 
LFS family history, and again it was absent from healthy subjects, now totaling 200 Americans 
(Lee et al., 2001). In contrast, Allinen et al. (2001) found the variant in seven out of 79 breast 
cancer families, but also in 13/200 healthy controls. Together with our study (III), this data indicates 
that the alteration is quite common in the Finnish population. In contrast, the variant appears rare in 
other populations as besides the studies by Bell et al. (1999) and Lee et al. (2001), Scutte and 
coworkers (2003) found the variant in only 2/737 familial breast cancer cases and in 1/723 control. 
The mutation is located in the FHA domain of the gene, in a region not directly involved in peptide 
binding (Li et al., 2002). The functional analysis have revealed that although the Ile157Thr mutant 
protein becomes normally activated (Wu et al., 2001), it cannot bind to p53 (Falck et al., 2001a), 
CDC25A (Falck et al., 2001b), or BRCA1 (Li et al., 2002). Further studies are underway in order to 
more fully understand the importance of this variant in breast cancer predisposition. 
There are now several additional reports where germline CHEK2 mutations have been looked for in 
LFS and LFL families. In a large study by Lee et al. (2001) where 59 LFS/LFL families were 
analyzed, a missense mutation Arg145Trp with presumably deleterious effect (Falck et al., 2001b; 
Lee & Chung, 2001; Lee et al., 2001; Wu et al., 2001; Li et al., 2002) was observed in a patient with 
breast carcinoma, sarcoma, and LFL family history. Additional variants that may confer cancer 
susceptibility, Arg3Trp and the above mentioned Ile157Thr, were found in two breast cancer 
patients from LFL and LFS families, respectively. Sodha and co-workers (2002b) found a 3 base 
pair deletion (483delAGA) in a breast cancer patient with LFL family background, but although 
absent in 300 healthy controls, the variant was not seen in tumors from affected relatives. No other 
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functionally significant alterations were observed among the remaining 25 LFS/LFL-families 
(Sodha et al., 2002b). No mutations were found in a study by Bougeard et al. (2001), and the only 
variant with potential significance in a study by Allinen et al. (2001) was the Ile157Thr. Strikingly, 
all potentially pathogenic CHEK2 mutations in LFS/LFL families were found in breast cancer 
patients. As complete segregation data is not available in any of the studies, it may be that CHEK2
mutations do not predispose to rather strictly defined multicancer phenotype of LFS/LFL, but 
instead may reflect, at least in part, the increased beast cancer susceptibility of the observed 
variants. As the CHEK2 1100delC is now shown to act as a low-penetrance breast cancer allele this 
may well be the case, although the modifying or additive effect on yet unidentified LFS/LFL 
susceptibility gene(s) cannot be totally disregarded.  
Other CHEK2 variants that may confer susceptibility to breast cancer have also been reported: a 
Thr59Lys in four breast cancer patients (Ingvarsson et al., 2002), an Arg117Gly in four breast 
cancer families (Sodha et al., 2002a; Schutte et al., 2003), and an Arg137Gln in one breast cancer 
family (Sodha et al., 2002a). Based on the results reported so far, it seems that CHEK2 is a low-
penetrance breast cancer gene that is responsible for a small fraction of breast cancer incidence. The 
largest contribution is through 1100delC mutation which is found in several populations, whereas 
other variants may have less apparent and/or geographically diverse relevance. Comparable to 
BRCA1 and BRCA2 germline mutations, 1100delC and possibly other genetic alterations in CHEK2
are likely to account for a varying fraction of familial breast cancer burden in different populations. 
First evidence of such geographical variation came from North America, where a relatively low 
frequency of 1100delC was observed both among healthy New Yorkers (0.3%) and in multiple-case 
breast cancer families with no BRCA1 or BRCA2 mutations (1%) (Offit et al., 2003). A total 
absence of the variant was observed in a Spanish study where none of the 400 familial breast cancer 
patients nor 400 healthy controls were found to carry a mutation (Osorio et al., 2003). Challenges in 
the near future include the determination of the 1100delC mutation frequency in various 
populations, and the resolving the importance of other observed variants. Whole-gene screenings 
are also warranted in order to identify additional alterations that may confer increased risk for 
developing cancer.  
Studies on somatic CHEK2 mutations in breast tumors have thus far been rare. Miller and 
coworkers (2002) found no mutations in 33 sporadic breast tumors, and Ingvarsson et al. (2002) 
detected only one mutation among 74 sporadic breast tumors (1.4%) and none in 45 tumors from 
BRCA2 999del5 carriers (Ingvarsson et al., 2002). Slightly higher mutation frequency was observed 
in a study by Sullivan and coworkers (2002), who found eight coding region mutations in 141 
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breast tumors (5.7%). Four of the mutations were detected in carriers of germline BRCA1 mutations 
(4/18), one in a sporadic case (1/78), and two in typical medullary breast carcinomas (2/25). None 
of the carcinomas from 20 BRCA2 carriers had a mutation. Interestingly, down-regulation of 
CHEK2 mRNA was observed in a significant fraction of tumors studied (16/34, 47%). This 
suggests that even though somatic mutations seem rare, CHEK2 inactivation may still be present in 
a substantial fraction of sporadic breast tumors (Sullivan et al., 2002).  Another intriguing 
observation was the high percentage of somatic p53 mutations in tumors with a somatic CHEK2 
mutation (7/8 tumors analyzed) (Sullivan et al., 2002). Concomitant inactivation of CHEK2 and p53
has also been detected in a colon cancer cell line HCT-15 (Falck et al., 2001a). Such simultaneous 
loss of both CHEK2 and p53 function is shown to result in selective advantage over that resulting 
from loss in either protein alone. This indicates the existence of non-overlapping checkpoint 
pathways that require either CHEK2 or p53, but not both (Falck et al., 2001a). It also argues against 
the hypothesis that CHEK2 mutations act as alternative to p53 mutations (Sullivan et al., 2002). 
CHEK2 is currently a target of an intensive research. The gene is most probably a tumor suppressor 
whose protein product mediates the signal of DNA damage from ATM to many downstream 
targets, including p53 and BRCA1. Mutations in CHEK2 lead to impaired checkpoint control and 
thus to increased cancer susceptibility. Besides increasing the risk for developing breast cancer as 
shown here (IV) and by Meijers-Heijboer et al. (2002), the central role of CHEK2 in cell-cycle 
control, and somatic mutations in various cancer types imply that CHEK2 may have a role in the 
tumorigenesis of other cancer types as well. So far, the 1100delC mutation, along with several other 
CHEK2 germline mutations, have been reported in prostate cancer (Dong et al. 2003). In Finland, 
statistically significant association between both the 1100delC and Ile157Thr mutations and 
hereditary prostate cancer have been observed (Seppälä et al., 2003). The 1100delC mutation has 
also been associated with families with both breast and colorectal cancer, leading even to a proposal 
of a new cancer syndrome of hereditary breast and colorectal cancer (HBCC) (Meijers-Heijboer et 
al. 2003). However, the observation was not confirmed in the study by Kilpivaara et al. (2003). No 
statistically significant increase in the 1100delC mutation frequency has been observed neither in 
familial nor in sporadic colorectal cancer, suggesting that its effect on colorectal cancer in the 
absence of breast cancer is very low or non-existent (Meijers-Heijboer et al. 2003; Kilpivaara et al. 
2003). Further studies are warranted to clarify the role of CHEK2 in various other cancer types. The 
mechanism of CHEK2 associated tumorigenesis needs also to be elucidated. So far, there is little 
and contradictory information on LOH in tumors from CHEK2 germline mutation carriers (Lee et 
al., 2001; Sodha et al., 2002a), suggesting that there may be also other inactivation mechanisms 
than the loss of the wild-type allele. In breast cancer, future tasks include identification of additional 
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low-penetrance genes similar to CHEK2. The challenge is not easy as there are probably many 
genes whose particular contribution may differ in various populations, and whose effect on breast 
cancer risk may be highly variable. But when such genes will be identified, the molecular 
background and pathogenesis of breast cancer becomes more fully understood. This, in turn, will 
eventually lead to the development of better diagnostic tools, individually targeted management 
strategies, and better surveillance.  
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7. SUMMARY AND CONCLUSIONS 
1. Germline mutations in BRCA1 and BRCA2 were observed in 1.8% of breast cancer patients 
unselected for family history or age at diagnosis. Strongest predictors of a mutation were the 
presence of ovarian cancer in a family or a breast cancer patient diagnosed at early age. In 
contrast, family history of site-specific breast cancer was not a compelling indicator of a 
mutation. Low frequency of BRCA1 and BRCA2 mutations in unselected breast cancer patients 
and in families with only two affected first-degree relatives (0.3%) indicate that mutation 
screening is not feasible in the general breast cancer population or in patients with only a 
modest family history. 
2. Only two clinical risk factors were found to have statistically significant correlation with a 
positive BRCA1 and BRCA2 mutation status when kindreds with multiple affected family 
members were analyzed by logistic regression. Associated variables were the number of ovarian 
cancer cases in a family and the age at diagnosis of the youngest breast cancer patient. By 
utilizing this information, a probability model that can be used to assess the likelihood of 
carrying a predisposing mutation in either BRCA1 or BRCA2 was devised. The model is a useful 
tool in genetic counseling and directing the mutation testing to potential mutation carrier 
families, thereby also improving the cost-effectiveness of the screening.  
3. All 36 large, site-specific breast cancer families with four or more affected relatives and no 
young patients (diagnosis below 40 years) were found not to carry predisposing mutations in 
either BRCA1 or BRCA2. Although some mutations may have been missed and some families 
may represent chance clustering of sporadic cases, these results suggest that there are additional 
susceptibility genes that may underlie a substantial proportion of familial aggregation of breast 
cancer.   
4. LFS is mainly due to germline mutations in p53. CHEK1 and CHEK2 were plausible candidate 
genes for underlying the remaining LFS and LFL families as their protein products regulate p53 
and somatic mutations in them have been observed in a wide variety of human tumors. 
However, no disease-associated CHEK1 mutations were detected, and CHEK2 is unlikely the 
gene for LFS as the possibly linked mutation is relatively common in healthy population and is 
shown to act as a low-penetrance allele in breast cancer. Therefore, there are still gene(s) to be 
discovered that completely unravel the molecular background of the syndrome.  
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5. The novel important finding in this study was the identification of CHEK2 as a new breast 
cancer susceptibility gene. The CHEK2 1100delC mutation is a low-penetrance allele that 
confers a modestly increased risk for developing breast cancer. The phenotypical consequences 
of the CHEK2 1100delC mutation differ from BRCA1 and BRCA2 mutations in that there is no 
association with ovarian cancer, age at diagnosis is similar to non-carriers, and mutations cluster 
in families with just a few affected relatives. High frequency of mutations in families with only 
a few affected family members −the most common type of breast cancer families−, suggests that 
the CHEK2 1100delC mutation is likely to make a significant contribution to familial 
aggregation of breast cancer at the population level.    
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